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ABSTRACT 
 
 
CATHY CASTELLON MOORE. The role of nonmuscle myosin II isoforms in hepatic 
stellate cell activation.  (Under the direction of DR. LAURA W. SCHRUM) 
 
 
The hepatic stellate cell (HSC) plays a pivotal role in the development of hepatic 
fibrosis. Regulation of liver microcirculation is a complex system where blood flow is 
under systemic and sinusoidal control. Upon a fibrogenic stimulus, quiescent HSCs 
transdifferentiates into activated myofibroblast-like cell and exert a sustained contractile 
force, resulting in hyperconstricted vessels. Early phenotypic changes observed during 
the transdifferentiation process include cell stretching and elongation of cytoplasmic 
processes. These changes facilitate proliferation and migration of HSCs to the areas of 
injury where excess amounts of collagen are deposited altering normal liver architecture 
and leading to liver dysfunction. Under chronic liver injury, this wound healing response 
perpetuates and impairs blood flow through the liver resulting in portal hypertension, 
which is one of the main clinical manifestations of liver fibrosis. Nonmuscle myosin II 
(NMM II) has been shown to be involved in cellular contraction, proliferation and 
migration. Using a whole-cell contraction assay and a selective myosin II inhibitor, we 
have demonstrated that myosin II is essential for HSC contraction. Additionally, the 
expression of NMM II isoforms in activated HSCs was upregulated. To further explore 
the mechanism of regulation, we altered in vitro conditions to more closely depict the in 
vivo environment using a matrix stiffness assay. Under these conditions, a minimal 
increase in NMM II-A and II-B mRNA expression was detected, which suggests that 
mechanical properties of the liver may regulate NMM II isoforms in HSCs. siRNA 
mediated isoform knockdown had no effect on culture-activated HSC contraction and 
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proliferation but cell migration was inhibited by 25%. Overall, our results demonstrate 
that myosin II isoforms play a critical role in the development of portal hypertension and 
HSC migration; however, the specific isoform responsible for this hypercontractile 
response has yet to be identified. Supported by NIH Grant AA14891. 
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CHAPTER 1: INTRODUCTION 
  
 
1.1 THE LIVER 
1.1.1 Architecture and Vasculature  
The liver is the largest internal organ and it is vital to survival. The primary cell 
type of the liver is the hepatocyte. The hepatocyte is responsible for cellular processes 
which include bile production, glucose storage and toxin removal [1]. The resident 
macrophages of the liver are the Kupffer cells (KCs), which reside within the specialized 
microvasculature of the liver, the sinusoid. The fenestrated cells lining the liver blood 
vessels are the sinusoidal endothelial cells (SECs), which are encircled by hepatic stellate 
cells (HSCs) (FIGURE 1.1). The HSC is a star-shaped cell that has several long 
extensions that protrude from the cell body and wrap around the sinusoids. Extracellular 
matrix components (ECM) comprised of collagen (type I, III, IV, and V), proteoglycans, 
glycoproteins and elastins provide scaffolding for liver architecture in the portal tracts, 
sinusoidal walls and central veins [2].  
The functional unit of the liver is the hepatic lobule, which is a hexagonal 
arrangement of parenchymal cells extending to the central vein (FIGURE 1.2). The portal 
triad consists of a bile duct and a terminal branch of the hepatic artery and portal vein. 
The liver has a dual circulation; it receives 75% deoxygenated blood from the portal 
venous system, which delivers blood from the small intestines, stomach, pancreas, and 
spleen and 25% oxygen-rich blood through the hepatic arterial system to the sinusoids 
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[1]. The blood supply branches into the sinusoidal network within the liver to optimize 
filtration and nutrient transport to the parenchymal cells. The blood drains into the central 
vein of each lobule, which combines into the hepatic vein and empties into the vena cava.  
Hepatocytes produce bile to aid in the digestion of lipids. The epithelial cells that 
line the hepatic bile duct are the cholangiocytes, which contribute to bile secretion by 
secreting water and producing bicarbonate to dilute the bile salts [1]. The bile canaliculus 
carries bile through hepatic ductiles to the common bile duct which drains into the 
gallbladder in humans. The gallbladder concentrates and releases bile in response to 
cholecystokinin stimulation in the duodenum in the opposite direction of blood flow [1]. 
The biliary network receives its blood supply through the peribiliary plexus which stems 
from the hepatic artery [3].  
1.1.2 Chronic Liver Disease and Portal Hypertension 
Chronic liver disease is the 12th leading cause of death in the United States as it 
accounts for nearly 30,000 deaths per year (CDC, National Center for Health Statistics, 
2005). One of the primary forms of liver disease is fibrosis, which results from liver 
injuries such as chronic hepatitis, alcoholic-liver disease and obstructive gallbladder 
disease. The liver is responsible for xenobiotic and ethanol metabolism; as a result, toxic 
metabolites can cause acute injury to the hepatocytes. The parenchymal cells lose 
microvilli and apoptose; SECs reduce blood flow to the hepatocytes by closing fenestra 
and KCs become activated by reactive oxygen species which initiate an inflammatory 
response and ECM deposition of type I collagen by the HSCs (FIGURE 1.3) [4]. This 
ECM provides a scaffolding complex in which SECs migrate to the site of injury to form 
new vascular beds for regenerating hepatocytes [5]. However, if the insult is alleviated, 
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matrix metalloproteinase (MMPs), such as MMP-13, are secreted by the HSCs to restore 
the normal tissue structure [6].  
Hepatic fibrosis results from normal wound-healing processes going awry and is 
the main cause of increased intrahepatic vascular resistance during liver injury [7]. When 
the injury is chronic, type I collagen deposition by HSCs occurs in excess of collagen 
break down by MMPs as a result of imbalance between fibrogenesis and fibrolysis [8]. 
Altered ECM architecture and mechanical distortion culminates in increased blood 
pressure in the portal venous system as blood must be diverted away from the liver [9]. In 
addition to occlusion and compression of the microvasculature, HSC hypercontractility 
contributes to increased resistance of the sinusoids leading to the clinical manifestation of 
portal hypertension which is characterized by both increased portal blood flow and 
augmented intrahepatic vascular resistance (FIGURE 1.4) [4, 7]. Consequences related to 
untreated portal hypertension are caused by the vasculature being shunted away from the 
liver.  
HSCs regulate intrahepatic vascular resistance and blood flow at the sinusoidal 
level by encircling long cytoplasmic projections around sinusoids and the ability to 
upregulate contractile proteins such as smooth muscle !-actin, myosin II and endothelin 
A and B (ETA and ETB) receptors [10-12]. HSCs respond to vasoactive constrictors such 
as endothelin-1 (ET-1), which activates the contractile apparatus [10-13]. Kawada et al., 
demonstrated that HSCs contract on silicone rubber membranes when exposed to 10nM 
of ET-1 as early as 2 minutes after incubation [14]. Moreover, HSCs seeded on hydrated 
collagen gels decreased the disc diameter proportionally dependent on cell number and 
collagen concentration. In vivo studies confirmed these results by intravital microscopy of 
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the hepatic sinusoids [12]. Zhang et. al., demonstrated that ET-1-induced constriction 
coincided at the site of HSC fluorescence and concluded that HSC hypercontractility may 
contribute to portal hypertension. It has also been demonstrated that average force 
generated by ET-1-induced contraction of a single HSC was 14000 dyn/cm
2
, which is 
greater than the sinusoidal pressure in cirrhotic rats [15]. Furthermore, a direct 
relationship between ET-1 mRNA receptors (ETA and ETB) and the degree of portal 
hypertension has been demonstrated in patients suffering from chronic liver injury [16, 
17].  
Alcohol abuse is a major cause of liver morbidity and mortality in the United 
States. Continued ethanol abuse culminates into four distinct disorders: alcoholic fatty 
liver disease (steatosis), hepatosteatosis (fatty liver and inflammation), fibrosis and 
cirrhosis. Five-year survival rates of these conditions vary between 25% and 60% [18]. 
While data suggest that alcoholic steatosis and hepatosteatosis can be reversible, the 
chronic progression of alcohol-induced fibrosis leads to irreversible cirrhosis in 10 to 
15% of alcoholics [19]. The severity of alcoholic cirrhosis depends on the stage and 
activity of the disease, subsequent alcohol intake and the occurrence of complications 
such as renal insufficiency, esophageal varicies and ascites resulting from portal 
hypertension, hepatic encephalopathy, bacterial infections or hepatocellular carcinoma 
[7].  
Chronic viral hepatitis is characterized by increased hepatocyte necrosis and 
inflammation of the portal triad caused by a viral load in excessive of 10
12 
cells/ day [20]. 
Hepatitis C (HCV) infection is the principal cause of nonalcoholic cirrhosis in the United 
States. Approximately 55-85% acute HCV cases progress into a chronic infection, while 
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only 5% of acute hepatitis B infections develop a chronic disease [21]. Excessive alcohol 
consumption accelerates the progression of cirrhosis in patients infected with HCV as 
compared to those who are not heavy consumers [22]. Additionally, HCV infected 
patients who abstained from alcohol consumption prolonged cirrhotic disease 
progression. Wiley et. al. showed that excessive alcohol consumption during interferon 
treatment impedes the patients’ response to antiviral therapy because alcohol has adverse 
effects on the interferon-generated signaling pathway which modulates immune 
responses [21]. Although the molecular mechanisms which regulate HCV progression to 
cirrhotic liver disease in alcoholic patients is not well understood, it has been suggested 
that alcohol may increase viral replication and/ or rapid mutation of HCV and/or suppress 
the inflammatory response by inhibiting the proper function of dendritic cells.  
Primary biliary cirrhosis is a progressive inflammatory disease of the liver that 
may be caused by a genetic predisposition to autoimmunity of the biliary network [23]. It 
is characterized by destruction of the interlobular bile ducts and the development of 
cirrhosis. Secondary biliary cirrhosis results from prolonged anatomical blockage of the 
extrahepatic biliary tree, which results in progressive hepatic injury. Liver injury induced 
by bile duct ligation (BDL) in experimental animals is a well-established method to 
investigate the pathogenesis of liver fibrosis [24]. The primary pathology of hepatic 
fibrosis induced by BDL is lesions surrounding the bile duct epithelium. The surgical 
maneuver of BDL obstructs the common bile duct and initiates proliferation of biliary 
cholangiocytes. Following rapid epithelial proliferation, sustained blockage of bile flow 
causes perpetual activation of HSCs in the periductal region, which promotes biliary 
fibrosis/cirrhosis.  
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Depending on the cause of hepatic injury, different disease types can lead to 
distinct zonal patterns of fibrotic expression (FIGURE 1.5) [25]. While viral hepatitis and 
primary biliary disease are periportal based (zone 1), alcoholic liver disease is pericentral 
based (zone 3) [26]. The location of initial scarring can be determined by an invasive 
liver biopsy, which can facilitate the diagnosis of disease progression. If properly treated, 
hepatic fibrosis can be a reversible process; however, chronic insult leads to the 
development of cirrhosis which results in nodule formation leading to altered hepatic 
function and obstructed portal blood flow [27].  
As the disease progresses, complications may arise such as: jaundice, hepatic 
encephalopathy, and/ or portal hypertension. Jaundice is typically characterized by 
yellow discoloration of the skin and conjunctiva of the eyes due to the high levels of 
bilirubin present in the vasculature. Hepatic encephalopathy results from decreased 
clearance of ammonia by the liver, which directly affects the brain. Portal hypertension 
not only perpetuates insult to the hepatic tissue by depleting oxygen to the cells but also 
gives rise to esophageal varicies and ascites.  If left untreated, variceal bleeding can lead 
to hemorrhage and death in a significant proportion of patients, as it accounts for 20-50% 
in-hospital mortality [28].  
Esophageal varices and ascites may develop when the hepatic venous pressure 
gradient (HVPG) increases from a normal pressure of 3-6 mmHg to 10mmHg. Variceal 
bleeding may occur when the HVPG rises above 12 mmHg. Currently, the treatment 
regime for patients suffering with acute variceal bleeding is endoscopic ligation in 
conjunction with pharmacological therapy for 2-5 days [29]. Vasoactive agents, such as 
somatostatin or vasopressin, indirectly decrease flow to the portal system by inducing 
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splanchnic vasoconstriction. Octreotide, a synthetic analogue of somatostatin, is 
commonly used as an adjuvant therapy in the United States to control variceal bleeding; 
however, it has been suggested that octreotide’s mechanism of action is associated with 
an increase in plasminogen activator protein [30]. Although the therapy decreases portal 
pressure, adverse effects associated with decreased blood clotting would be detrimental in 
the clinical setting of uncontrolled variceal bleeding. On the other hand, terlipressin, a 
vasopressin analogue, is most typically prescribed in European countries with the added 
benefit that it can be administered by intermittent intravenous injections rather than by 
continuous intravenous administration. Long-term treatment to manage uncontrolled 
bleeding may also include balloon tamponade, banding or sclerotherapy in conjunction 
with beta-blockers, which significantly reduce the risk of a first hemorrhage in patients 
with large varices and improves survival [31].  
Besides removal of insult, liver transplantation remains the only effective 
treatment for end-stage liver disease; however, a huge gap remains between the number 
of people who need a liver transplant and the number of organs available. According to 
the 2008 U.S. Organ Procurement and Transplantation Network and the Scientific 
Registry of Transplant Recipients Annual Report, the number of patients awaiting a liver 
transplant at year-end peaked in 2001; however, a decrease of 3.8% was observed in 
deceased donor liver transplants in 2007 (FIGURE 1.6). This drop was due largely to 
decreases in donation, particularly by living donors. There were 423 (6.3%) fewer living 
donors in 2007 than in 2006. Similarly the number of organs recovered for transplant 
from deceased donors has also moderately declined (7,084 in 2006 vs. 7,029 in 2007). 
Although the gap between the number of candidates and recipients has been mildly 
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shrinking, there remains a critical for the development of treatments to prolong the life 
until a suitable organ is available. In addition, not all patients of end-stage liver disease 
are suitable candidates for liver transplantation. Generally, organs are transplanted to 
patients with the highest degree of survival. Patients positive for AIDS or HIV, with 
irreversible brain damage, multi-system failure that is not correctable by liver 
transplantation, malignancy outside the liver, infections outside the hepatobiliary system, 
active alcohol or substance abuse are not eligible. Therefore, treatment generally focuses 
on preventing progression and complications of the disease. Targeting portal 
hypertension may improve quality of life and prolong survival of patients awaiting 
transplantation by treating esophageal varicies and ascites and restoring proper hepatic 
microcirculation. 
1.2 HEPATIC STELLATE CELLS 
1.2.1 Embryonic Origin  
The hepatic stellate cell (HSC) is a non-parenchymal cell type distributed 
homogenously throughout the perisinusodial space of Disse and comprises 15% of the 
liver [32]. The embryonic origin of HSCs has been inconclusive, however the majority of 
studies suggest HSCs may be derived from the endoderm or the septum transversum. 
Based on HSC expression of the transcription factor, Foxf1, in the developing and adult 
liver, a septum transversum-derived origin is implicated [33]. Additionally, Foxf1 +/- 
mice exhibited abnormal liver repair following injury due to decreased collagen 
production, reduced HSC activation and increased pericentral hepatic apoptosis. In 
support of an endoderm-derived origin, HSCs and hepatoblasts, which are 
undifferentiated progenitor cells originating from the ventral foregut endoderm, share a 
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common origin based on the expression cytokeratins in both cell types [34, 35]. These 
cells are present in the adult liver and can ultimately differentiate into hepatocytes and 
cholangiocytes [36]. 
Conversely, a neural crest-derived origin of HSCs has also been suggested based 
on the expression of a number of neural/neuroendocrine markers such as nerve growth 
factor, nestin, neural cell adhesion molecule, glial fibrillary acidic protein and cellular 
prion protein and based on their proximity to autonomic nerve endings [37]. However, 
the likelihood of neural crest origin of HSCs was refuted by a study using a transgenic 
mouse line expressing yellow fluorescent protein (YFP) in all neural crest cells and their 
derivatives [38]. While YFP was abundantly expressed in neural crest cells bifurcating 
from the neural tube and in all known neural crest-derived structures and cell populations, 
no detectable YFP expression was seen in the developing liver or in the HSC. This 
evidence further supports an embryonic origin derived from either the septum 
transversum or the endoderm. 
1.2.2 Structure and Function in Normal and Injured Liver 
In the normal quiescent state, HSCs project extensive cytoplasmic processes 
through the space of Disse and reach between hepatocytes and endothelial cells wrapping 
around neighboring sinusoids similar to tissue pericytes [39]. The expression of smooth 
muscle proteins and the strategic anatomical location of these cells suggest a functional 
role in maintenance of vascular tone much like a smooth muscle cell. The HSC is the 
main storage site of retinol in the liver (80-90%), similar to an adipocyte, with the 
remaining quantity being stored in hepatocytes awaiting release into the circulation to 
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maintain blood plasma levels of 2µM [40, 41]. HSCs also play a vital role in normal 
matrix maintenance and remodeling, similar to a fibroblast.  
Upon a fibrogenic stimulus, the quiescent HSC transdifferentiates into an 
activated myofibroblast-like cell (FIGURE 1.7) [42]. Acute injury to the hepatocytes 
such as an increased viral load or chronic ethanol consumption initiates activation of the 
normal wound healing response. The metabolism of ethanol results in increased 
production of acetaldehyde and reactive oxygen species, which activates KCs 
subsequently stimulating release of cytokines and contributing significantly to HSC 
activation. HSCs proliferate, lose retinol droplets, increase expression of smooth muscle 
!-actin and secrete excess type I collagen for matrix repair [42-44]. Increased micro-
projections from the myofibroblast allow for increased chemotactic signaling, which 
induces cellular migration to the site of injury [45]. Because of the anatomical location 
and increased contractile apparatus expression, it has been suggested that HSCs are 
capable of disrupting liver blood flow by hypercontracting, impeding microcirculation 
and contributing to portal hypertension [14, 46]. When the insult subsides, fibrosis 
resolves; however, if the injury is chronic, then the activated phenotype perpetuates and 
contributes to the progression of cirrhosis [6].  
1.2.3 Extracellular Matrix Production and Degradation 
In a healthy liver, HSCs produce ECM components for normal basement matrix 
remodeling including collagen (type I, III, IV, and VI), proteoglycans and glycoproteins 
[5, 47]. Type I, II, and V collagen is mainly confined to the portal tract and central vein 
wall, while type IV collagen along with laminin and entactin-nidogen form the basement 
membrane along the sinusoidal wall in the space of Disse [48]. In addition, HSCs 
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produce several types of MMPs (MMP-2, MMP-9, MMP-13, and stromelysin), which 
degrade ECM components [49-54]. In order to maintain basement membrane balance, 
HSCs produce tissue inhibitors of MMPs (TIMPs; TIMP-1and TIMP-2) [55]. Other 
distinct cell types also contribute to the production of collagens for hepatic architectural 
maintenance. Myofibroblast residing in the portal connective tissue, perivascular 
fibroblasts associated with the portal and central veins and periductular fibroblasts 
residing along the cholangiocytes of the bile duct all contributed to ECM maintenance 
[56]. Additionally,  myofibroblast of bone marrow origin may contribute to the collagen 
accumulation within the liver [57]. Because ECM ultrastucture plays a role in the proper 
delivery of oxygen and nutrients across the fenestrated SECs, perisinusodial space of 
Disse and subsequently to the paraenchymal cells of the liver, it is important to 
understand the changes that occur during fibrosis.  
In a fibrotic liver the balance of ECM composition is quantitatively increased (3-5 
fold) [58]. Increased secretion of fibrillar collagens, specifically type I collagen, in the 
space of Disse, replaces the low density basement membrane with fibrous scar matrix 
(FIGURE 4) [59]. Type I collagen is synthesized by the coordinated expression of 
procollagen !1(I) and !2(I) mRNA [60]. Two pro-COL1A1 and one pro-COL1A2 
polypeptide chains form the triple helix procollagen structure, which combine with other 
molecules to form larger collagen fibrils [60]. Both transcriptional and post-
transcriptional modifications regulate collagen synthesis within the HSC [61]. At the 
transcriptional level, several repressor and enhancer elements, such as cytokine response 
elements, within the promoter of both subunits
 
contain regulatory regions [62-64]. 
Additionally, DNA methylation of the first intron at different regulatory regions also 
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enhances transcription [60]. At the post-transcriptional level, it has been shown that not 
only does procollagen !1(I) mRNA stability increase from 1.5 hours in quiescent HSCs 
to greater than 24 hours in activated HSCs, steady state levels also increase 60 to 70-fold 
[65]. Increased mRNA stability within the activated HSC is mediated by an RNA-binding 
protein on the 3’-untranslated region of the procollagen !1(I) mRNA and through a stem-
loop binding structure in the 5’ end of the procollagen !1(I) mRNA [65]. Both increased 
type I collagen stability and secretion further contribute to scar matrix accumulation and 
thus impedes fibrotic resolution. 
Increased matrix stiffness observed in liver fibrosis has been associated with 
perpetual HSC activation, which results in a shift of ECM components from a basal to a 
fibrillar matrix. Signaling from the ECM to the HSCs occurs through several specific cell 
membrane receptors such as integrins, discoidin domain receptors and dystroglycan [66-
68]. Type I collagen stimulates cell adhesion by interacting with integrin !1"1 to 
stimulate focal adhesion kinase (FAK) phosphorylation, activation of phosphoinositide 3-
kinase (PI3K), which leads to cellular migration [69, 70]. Additionally, MMPs are 
capable of cleaving ECM and cell surface molecules, which alter cell-matrix and cell-cell 
interactions, affecting biological function and growth factor release. Transforming 
growth factor " (TGF") can directly affect matrix stiffness by suppressing MMPs and 
activating TIMPs in HSCs[71]. Additionally, TGF" may also signal through the Smad 
pathway directly altering matrix stiffness. HSCs isolated from mice overexpressing 
Smad3, a Smad family member, demonstrated an increase in stress fiber formation and 
focal adhesions following culture activation [72].  Although Smad3 overexpression did 
not increase smooth muscle !-actin expression (marker of HSC activation), it was shown 
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to be the determining factor in stress fiber organization, thus playing an important role in 
matrix rigidity of the fibrotic liver.  
Culturing freshly isolated HSCs on uncoated plastic tissue culture dishes mimics 
the in vivo environment of liver fibrosis and activates quiescent HSCs. In cirrhotic 
patients, liver stiffness measurements range from 12.5 to 75.5 kPa [73]. Therefore, 
altering matrix stiffness regulates HSC activation [73]. The quiescent phenotype can be 
maintained in culture on a laminin-rich gel (Matrigel) that mimics the effects of a normal 
basement membrane. Additionally, HSCs are more fibrogenic when grown on type I 
collagen in response to TGF" than on type IV collagen [74, 75]. Noninvasive strategies 
for the diagnosis of hepatic fibrosis have been measured by transient elastography 
(FibroScan) [76]. By using a mechanical pulse at the skin surface, FibroScan can measure 
the velocity of the wave, which directly correlates to liver stiffness, by ultrasound. The 
manifestation of matrix stiffness as a regulator of HSC activation strengthens the 
diagnostic potential of this screening method.  
1.2.4 Retinol Production, Receptor Expression and Cytokine Secretion  
In the liver, HSCs are responsible for retinoid metabolism, immunoregulation and 
the secretion of cytokines and growth factors. Most retinoid is stored in cytoplasmic 
vesicles in the form of retinyl esters [77]. Dietary vitamin A is esterified with long-chain 
fatty acids and packaged into chylomicrons for transport through lymphatic draining 
vessels from the intestines to the hepatocytes [40]. The retinyl esters are then hydrolyzed 
to retinol and transferred to HSCs mediated by retinol binding protein (RBP) [78]. The 
lipophillic compounds exhibit the characteristic blue autofluorescence of quiescent HSCs 
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when excited with a UV light and measured with a DAPI (4',6-diamidino-2-
phenylindole) filter (~328nm $) (FIGURE 1.8) [79].  
In addition to retinoid production, HSCs also play a role in the complex interplay 
of the hepatic immune system. Activated HSCs produce chemokines such as monocyte 
chemotactic peptide (MCP)-1, macrophage colony-stimulating factor (MCSF), CCL21, 
RANTES and CCR5 to amplify the inflammatory response by inducing infiltration of 
mono- and polymorphonuclear leukocytes [80-82]. Similar to antigen presenting cells, 
HSCs also express toll-like receptor (TLRs) -4 and -2, which allow them to respond to 
both Gram-negative and -positive bacterial cell components such as lipopolysaccharide 
(LPS) and peptidoglcan, respectively [83, 84]. Subsequently, HSCs express the 
costimulatory molecules CD38 and CD40, which stimulate the secretion of 
proinflammatory molecules interleukin-6 and -8 (IL-6 and IL-8), respectively [85, 86].  
IL-6 is a key cytokine in the hepatic acute injury response, which induces 
production of C-reactive protein, a key inflammatory marker. IL-6 has been shown to be 
critical in liver regeneration following transplantation [87], hepatoprotective in CCl4 
induced injury [88] and is required for wound healing in a hepatectomy model [89, 90]. 
However, in a fibrotic liver, the role of IL-6 is ambiguous, since IL-6 secretion 
contributes to the fibrotic progression [91, 92]. Additionally, IL-6 has been shown to up-
regulate collagen production in many collagen-producing cell types, including activated 
HSCs [93-95]. Conversely, HSCs exhibit a dual role mediated by oxidative stress in a co-
culture system with KCs [95]. Finally, activated HSCs produce IL-6 as well as respond to 
it [93, 96-98]. While IL-6 has been analyzed in multiple injury models, the role of IL-6 in 
HSC transdifferentiation has yet to be fully elucidated.  
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Although IL-6 is a potent fibrogenic cytokine, TGF" has been described as the 
most potent fibrotic mediator of hepatic fibrosis. TLR-4 stimulates the secretion of latent 
TGF" in response to acute injury. Three isoforms of TGF! exist, with TGF!1 being the 
most potent fibrogenic stimuli for HSCs and predominately acting in the immune 
response [99]. HSC activation upregualtes TGF"-receptor (TGF"-R) expression in HSCs, 
which stimulates retinol release, matrix deposition, contractility and chemotaxis mediated 
through Smad 2 and 3 [100-105]. Activated Smad 2 and 3 recruit Smad 4 to form a 
heterotrimeric complex that translocates to the nucleus and regulates gene transcription to 
stimulate the production and deposition of fibrillar EMC components such as type I and 
III collagen. HSCs also secrete TGF! and epidermal growth factor (EGF), which 
stimulates hepatocyte proliferation during regeneration, HSC mitosis, and creates an 
autocrine stimulus for perpetual HSC activation [101, 106-108]. Although HSCs are the 
main source of TGF! secretion, KCs and platelets can also produce this cytokine [109].  
In order to counteract the proinflammatory cytokines IL-6 and TGF", 
transcription factors in the activator protein-1 family, interleukin-10 signaling mediates 
the inhibition of type I collagen production and thus reduces inflammation [110, 111]. 
Other soluble factors such as fibroblast growth factor (FGF) and interferon # (IFN#) also 
reduce extracellular matrix deposition [112, 113]. Overall, the numerous cytokines and 
receptors HSCs secrete and express suggest a fundamental role in hepatic immunology.  
1.2.5 Contraction 
 In the normal liver microcirculation autoregulation is delicately balanced by 
potent vasoactive modulators, such as nitric oxide (NO) and endothelin-1 (ET-1) [32, 
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114]. Several studies have shown that ET-1 levels are elevated in patients with cirrhotic 
livers, while levels of NO are decreased [115, 116].  
NO, which is a potent vasodilator produced by SECs, is a gaseous compound 
biosynthesized endogenously from L-arginine and oxygen by nitric oxide synthase (NOS) 
and by reduction of inorganic nitrate. NO production is attributed to the activity of the 
inducible NOS isoform (iNOS) in HSCs [117]. NO binds guanylate cyclase, which 
increases cyclic guanosine monophosphate (cGMP) and activates protein kinase G (PKG) 
to regulate intracellular calcium in smooth muscle cells [118]. NO production inhibits 
calcium influx, which decreases contraction [119]. Exogenous NO has been shown to be 
capable of preventing ET-1 induced contraction as well as induce relaxation of pre-
contracted gels [114]. In the normal liver, the NO donor diethylamine NONOate (DEAN) 
significantly increased cGMP production and reduced basal HSC contraction, while PKG 
chemical inhibition abolished the observed DEAN effects suggesting a cGMP-dependent/ 
PKG-dependent and -independent pathways [120]. These studies also demonstrated that 
cGMP/ PKG signaling is impaired in activated HSCs contributing to an imbalance of 
vasoactive modulators in the injured liver [120].  
Endothelins are potent vasoactive substances synthesized by nonparenchymal 
cells of the liver, predominately in SECs in a prepro-form (200 amino acids) [121-123]. 
Three isoforms have been identified; ET-1, -2, and -3 [124]. Furin-like enzymes induce 
proteolytic processing of preproET to big endothelin (Big ETs; 38-41 amino acids). Big 
ETs are cleaved by endothelial converting enzymes at Trp-21-Cal/Il3-22 to yield the 21 
amino acid mature peptide (ETs). ETs diffuse and bind to the guanine protein-coupled 
receptors ETA and ETB on neighboring cells or act in an autocrine manner [14, 125, 126]. 
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ET-1 stimulation of ETA receptors on smooth muscle cells lead to cellular contraction, 
while ETB receptors display a similar affinity for all three ET isoforms and stimulate NO 
release. Presence of ETA and ETB receptors suggests that HSCs are capable of 
modulating vascular tone [121, 127]. Furthermore, in vitro results demonstrated that 
SECs release excessive ET-1, which has a stimulatory effect on HSC proliferation, 
!SMA expression and contraction of collagen lattices [14, 122]. This data was confirmed 
in vivo by showing that ET-1 induces significant sinusoidal constriction at the sites of 
HSCs but not at the sites of KCs or SECs [128]. Additionally, in a cirrhotic model, ET 
receptor density was increased on HSCs [129].  
 Simulation of ETA receptors induces HSC contraction through both a calcium- 
dependent and independent medium (FIGURE 1.9) [127].  Similar to what is observed in 
smooth muscle cells, ETA receptor binding increases the cyclic adenosine 3’, 5’-
monophosphate (cAMP) levels in HSCs [130]. Increased levels of calcium are generated 
by cAMP-induced activation of phospholipase C-", cleavage of phosphatodyinositol 4,5-
biophosphate and release of 1,4,5-triphosphate [122]. Influx of calcium activates 
calmodulin-dependent myosin light chain kinase (MLCK), which phosphorylates and 
subsequently stimulates the ATPase activity of myosin II and thus contractile force 
generation [131].  
Conversely, previous results suggest that ET-1 predominately stimulates 
activation of calcium-independent pathways mediated through the RhoA signaling 
cascades [132]. RhoA is a small monomeric GTPase that is inactive in the GDP bound- 
and active in the GTP bound-state. GTPase activating proteins (GAPs), guanine 
nucleotide exchange factors (GEFs) and guanine nucleotide dissociation inhibitors 
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(GDIs) regulate the state of activation. While GEFs accelerate GTP hydrolysis, GAP and 
GDI increase GDP association and thus RhoA activation [133]. RhoA activation 
stimulates Rho kinase (ROCK), which inhibits myosin light chain (MLC)-phosphatase 
and directly phosphorylates MLC both resulting in enhanced phosphorylation of myosin 
II, stress fiber formation and cellular contraction.  
By using a selective inhibitor for ROCK (Y-27632), it has been suggested that 
HSC contraction is predominately mediated through the RhoA pathway. Kawada et. al., 
demonstrated that HSCs cultured on collagen lattices in the presence of Y-27632 failed to 
contract when stimulated with ET-1 [134]. This study also showed that myosin II 
phosphorylation was decreased while !SMA expression remained stable indicating that 
ROCK inhibition directly impeded myosin II phosphorylation. Furthermore, ROCK 
inhibition, using Y-27632, decreased portal pressure in vivo and thus could potentially 
attenuate portal hypertension [134]. Treatment with Y-27632 also impeded progression 
of hepatic fibrosis as shown by decreased collagen accumulation and HSC activation, 
which has been shown to be mediated through the angiotensin II signaling pathway [135]. 
Therefore, distinguishing between ROCK-induced contractile properties and other 
fibrogenic responses requires a more selective inhibitor of HSC contraction.  
A closer examination of the two distinct contractile pathways demonstrated that 
rearrangement of surrounding matrix, and thus gel contraction of collagen lattices seeded 
with myofibroblasts, was associated with rearrangement of central stress fibers induced 
by the Rho kinase-mediated signaling cascade, while the peripheral stress fiber system 
depended more on the calmodulin-dependent MLCK activity [136]. Although the 
calcium-independent pathway appears to predominate in HSC hypercontractility, these 
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findings suggest that the actomyosin-based cytoskeletal actions can be functionally 
diverse depending on the signaling cascade.  
Collectively, an imbalance of vasoactive modulators leads to HSC 
hypercontractility and increases portal pressure by decreasing sinusoidal diameter. In 
addition to the change in production of vasoactive substances in the injured liver, the 
contractile machinery in activated HSCs is also upregulated, which confers an increase in 
contractile potential.  
1.2.6 Proliferation and Migration 
Activated HSCs not only contribute to the fibrotic condition through increased 
vascular resistance but also through expanding the cell number through proliferation. 
Platelet-derived growth factor (PDGF) is the most potent proliferative stimulus for HSCs 
and is mainly produced by KCs [4, 137, 138]. This cytokine exists either as a homodimer 
(PDGF-BB) or as a heterodimer (PDGF-AB), the dimers being connected through 
disulfide bonds. In order to enhance proliferation and regulate cell survival, PDGF-BB 
stimulates PDGF receptor expression and thus the PI3K-mediated signaling cascade, 
which leads to a multitude of downstream effects including Akt and ribosomal kinase S6 
kinase (p70
S6K
) activation (FIGURE 1.10) [139]. PI3K inhibitors, such as wortmannin 
and LY294002, have both been shown to reduce PDGF-dependent proliferation [69, 70]. 
Furthermore, wortmannin inhibition of PI3K also reduced PDGF-simulated activation of 
extracellular-signal regulated kinase (ERK) activity and c-fos mRNA levels, which is 
dependent of ERK activation, suggesting that cross- talk occurs between the PI3K and 
mitogen-activated protein kinase (MAPK) pathways in PDGF-stimulated HSCs [140]. 
PDGF stimulation can also directly activate MAPK pathway through the Ras-Rac-Raf 
 20 
 
complex thereby activating c-Jun nuclear kinase (JNK) and ERK [141]. However, direct 
inhibition of p
38
 MAPK pathway by SB203580 increased HSC proliferation indicating a 
dual mechanism mediated by MAPK activation regulating HSC mitosis [142].  
In addition, activation of p70
S6K
 is also critical for HSC proliferation, collagen 
production and cell survival. The p70
S6K
 chemical inhibitor, rapamycin, blocks PDGF-
stimulated proliferation in culture-activated HSCs [137, 143]. Furthermore, rapamycin 
also reduces the !1 (I) collagen gene and collagen protein levels, indicating that p70S6K is 
positioned downstream of Akt in the PI3K signaling pathway. Finally, studies PDGF-
stimulated cells increases FAK activity and genetically blocking this pathway inhibits 
PI3K activity and thus HSC proliferation [144]. 
Activated HSCs increase secretion of PDGF as wells as upregulate their tyrosine 
kinase receptor expression (PDGF receptor) during liver injury, which induces 
proliferation and stimulates cell migration [145, 146]. In addition to PDGF-BB, ET-1, 
TGF"1 and/ or EGF have been associated with chemotactic HSC migration [45, 147, 
148]. Based on exogenous ET-1expression, it has been shown that wound-induced 
migration of HSCs is associated with guanine receptor -mediated signaling of the 
actomyosin cytoskeleton (FIGURE 1.10) [148]. Additionally, HSC cytoplasmic 
projections facilitated the response of  PDGF signaling and transduce this stimulant into 
mechanical forces that induce cell spreading at the leading edge, movement of the cell 
body towards the chemotactic signal and retraction of the trailing edge of the cell [45]. 
Thus endogenous ligand antagonists or receptor blockage to PDGF activity is a promising 
therapeutic approach to suppressing fibrogenesis. 
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1.3 MYOSIN 
1.3.1 Structure and Function 
Molecular motors play important cellular roles in actin-based motility, vesicle 
transportation, endocytosis, phagocytosis, stereocilia formation, cytokinesis and 
contraction. Myosins are a large super-family of molecular proteins found in eukaryotic 
tissues that bind actin filaments in order to generate force using ATP hydrolysis [149]., 
twenty-five different classes have been characterized based on amino acid sequences in 
their ATP-hydrolyzing motor domains. Myosins are comprised of three subdomains: the 
head region, which interacts with actin and binds ATP, the tail region, which anchors and 
positions the head region and the neck region, which binds either the MLCs or 
calmodulin (FIGURE 1.11). In many myosins, the tail region is capable of forming coil-
coil complexes, which allows the molecules to form dimers. Analysis of different myosin 
structural cores demonstrates a strong conservation of the head regions’ sequences but an 
enormous variability in the tail regions, while the neck regions maintain a conserved 
consensus sequence of IQXXXRGXXR, referred to as IQ motifs [150]. The number of 
IQ motifs in the neck regions ranges from zero to six in the different myosin classes. The 
differences in domain structure allow the different classes to perform specific cellular 
functions at the appropriate kinetics. Myosin V, which is an organelle transporter, has a 
much longer neck region than myosin II, and can traverses actin filaments by taking 30-
40 nanometer steps with each cross-bridge cycle. In contrasts, myosin II takes 5-10 
nanometers steps and functions as an assembly of motors to produce a contractile force in 
cells [150]. 
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 Myosin II also termed “conventional myosin” is responsible for generating 
contractile forces [151]. Myosin II molecules can be subdivided further into distinct 
classes based on different amino acid sequences in the motor domain: the sarcomeric 
myosin II from muscle cells (skeletal, cardiac and smooth), nonmuscle myosin II,  and 
myosin II from lower eukaryotic species and fungi [149]. Human nonmuscle myosin II is 
weakly homologous (33%) to sarcomeric myosin, while they exhibit a higher homology 
as compared to smooth muscle myosins (72%) [152]. Generally, the hexameric myosin II 
protein, with a molecular weight of 171-244 kDa, consists of two identical heavy chains 
(MHCs) each with two associated MLCs [151]. The individual MHCs (head regions) 
consist of a catalytic motor domain, an !-helical neck region containing two IQ motifs 
and a coil-coil tail region [151]. The amino-terminal motor domain contains a nucleotide-
binding region that is opposite a deep pocket that transverses the actin-binding domain 
[153]. Small conformational changes in the ATP binding region are coupled to large 
swings of the neck region [153]. The tail region forms antiparallel complexes, which 
polymerize hundreds of myosin molecules in thick filaments of skeletal muscle cells or as 
few as 28 myosins in nonmuscle cells [154]. The actin-associated proteins, troponin and 
tropomyosin, are the primary regulatory molecules of skeletal and cardiac muscle 
contraction; whereas, phosphorylation of the 20kDa MLC is the predominate regulator of  
nonmuscle and smooth muscle myosin [155, 156]. 
The activity of smooth muscle and NMM II has also been shown to be regulated 
through phosphorylation of the MHC by casein kinase II, small GTPases, such as Rho 
and Rac, and PKC [157-159]. While casein kinase II inhibits the assembly of the coiled-
coil tail region of smooth muscle myosin in bovine aorta, Rac phosphorylation of the 
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MHC induces filament instability and promotes disassembly of actomyosin complexes 
[160]. Furthermore, insulin secretion in rat pancreatic islet cells can be activated by PKC-
mediated phosphorylation of the MHC, independent of MLC phosphorylation [161].  
In order to determine specific myosin II cellular functions, pharmacological 
agents have been used including, 2,3-butanedione monoxime (BDM), N-benzyl-p-toluene 
sulfonamide (BTS), Y-27632 (ROCK inhibitor) and blebbistatin [153, 162-164]. BDM 
inhibits myosin ATPase activity by blocking myosin II in a weak binding contraction 
after ATP binding [165]. BTS on the other hand blocks skeletal muscle myosin II by 
competitively interacting with the myosin II binding site on F-actin [166]. Y-27632 
inhibits the Rho pathway by blocking the upstream stimulator of myosin II activity, 
ROCK. However inhibiting the Rho pathway blocks a wide range of cellular functions 
such as contraction, migration, apoptosis and proliferation via the MLC phosphorylation, 
LIM-kinase, Akt and the ERK pathway, respectively [167]. Therefore, using a chemical 
inhibitor, such as blebbistatin, which is more potent and selective than BDM or BTS, 
may prove to be beneficial in delineating the specific role of myosin II [168]. Blebbistatin 
is a reversible pharmacological inhibitor that preferentially binds to the ATPase 
intermediate with ADP and phosphate bound at the active site (myosin-ADP-Pi). 
Blebbistatin exerts its mechanism of inhibition by limiting phosphate release from the 
actomyosin complex, which prevents rigor of the myosin molecule and actin filament 
sliding. While studies have shown blebbistatin is an inhibitor of skeletal muscle and 
NMM II activity with minimal effects on smooth muscle myosin II, others have shown 
that blebbistatin is specific to smooth muscle myosin II [164, 169-171]. Chemical 
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inhibition of myosin II activity is useful in exploring the functional role of the molecular 
motor within the cell. 
1.3.2 Smooth Muscle Myosin II  
Although the structural cores of the myosin II classes are homologous, the minor 
amino acid alterations in the heavy and light chains alter kinetic and biochemical 
properties of the motor [172]. Smooth muscle myosins can be classified into two 
categories: tonic and phasic [173]. While tonic smooth muscle has the capacity to 
maintain force, force maintenance in phasic smooth muscle is less apparent. Generally, 
stimulation of smooth muscle results in an initial period of force activation followed by 
force maintenance. Both intracellular calcium and MLC phosphorylation increase rapidly 
during force activation before falling to a lower steady state level [174]. Similarly, the 
maximum velocity of muscle shortening (Vmax) increases to a peak then falls to a lower 
level during force maintenance [174]. This state of force maintenance with low levels of 
calcium, MLC phosphorylation and Vmax is referred to as the “latch state” [174, 175]. It 
has been suggested that the molecular basis for the latch state may be due to 
dephosphorylation of active cross-bridge cycling, dynamic cytoskeletal arrangements and 
the slow release of ADP from both phosphorylated and dephosphorylated smooth muscle 
myosin [176-178]. 
Four isoforms of smooth muscle myosin II are derived from one gene capable of 
alternative splicing; SM 1-A, SM 1-B, SM 2-A and SM 2-B [179-182].  The SM 1 
isoforms contain a phosphorylation site for casein kinase II, suggesting a regulatory role 
for filament assembly and thus differences in contraction rates. Furthermore, a 7-amino 
acid insert in the loop-1 region at the 25/50kDA domain junction in the head of SM B 
 25 
 
may be responsible for modulating actomyosin kinetics [183]. SM B knockdown in 
transgenic mice has been shown to result in a slower smooth muscle phenotype [184]. 
Additionally, two isoforms of the MLC are formed in smooth muscle: LC17a and LC17b 
[185]. While expression of LC17b slows the actin activated ATPase, expression of LC17a 
and SM B correlates to a faster smooth muscle phenotype.  
1.3.3 Nonmuscle Myosin II  
In nonmuscle cells, three isoforms of myosin II encoded by different genes have 
been identified in vertebrates, NMM II-A, II-B and II-C [186-188]. Each isoform has 
been mapped to different chromosomes. By genomic sequence analysis, the NMM II-A 
gene, MYH9, is mapped to 22q12.3-q11.2, while the NMM II-B gene, MYH10, is 
mapped to 17q13 [187]. The NMM II-C gene, MYH14, is mapped to chromosome 
19q13.33 [189]. In the motor domain, the isoforms are 64-80% identical at the amino 
acid level. The distinct variations and enzymatic properties of each isoform are important 
in modulating the kinetic properties of the cell and allow for fine tuning of specific 
biological functions [190].  
It has been shown that mutations in the MYH9 gene coincide with the autosomal 
dominant giant-platelet disorders May Hegglin anomaly (MIM 155100), Fechtner 
syndrome (MIM 153640), Epstein Syndrome (MIM 153650) and Sebastian syndrome 
(MIM 605249) [191]. Furthermore, the homozygous deletion of MYH10 in mice was 
lethal in embryos due to heart and brain defects, while mutations in MYH14 exhibited 
hearing loss as indicated by decreased auditory brainstem responses [192].  
Higher organism tissues express relatively ubiquitous levels of all three isoforms; 
however, it has yet to be determined whether these proteins play redundant, overlapping 
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or distinct roles in performing various mechanical functions in the cell. While NMM II-A 
is only expressed in chicken intestinal epithelial cells and platelets, NMM II-B is 
predominately expressed in neuronal tissue [193, 194].  Both isoforms are distributed 
along stress fibers in a linear fashion and localization varies between different cell types 
[195]. Generally, NMM II-A co-localizes with actin filaments at the leading edge of cells, 
while II-B co-localizes to the cellular cortex [195]. The regional variations in the 
different myosins suggest that each isoform may be responsible for specific molecular 
functions within the cell that potentially correlate to the kinetics of each isoform.  
Investigating the mechanochemical cycle of NMM II-A, II-B and II-C provided 
kinetic evidence that all three isoforms have slow ATPase activities as compared to other 
myosin II classes (NMM II-A: Vmax=1.2/s; KATPase=7.4µM; NMM II-B: Vmax=0.28/s; 
KATPase=12.7µM; NMM II-C: Vmax=0.55/s; KATPase=16.5µM;). NMM II-B has a higher 
ADP affinity than NMM II-A and spends the majority of its kinetic cycle bound to actin. 
With a lower ADP affinity, NMM II-A spends a smaller fraction of its kinetic cycle 
attached to actin [190]. The slower ADP release and long actin attachment time make 
NMM II-B an ideal candidate for long term force maintenance. Based on these 
calculations, one group determined that a transition between ADP states is the rate 
limiting step in the kinetic schematic [154]. Contrarily, others have shown that the 
phosphate release is the rate-limiting step [190].  The differing views explain the drastic 
differences in the reported duty ratios of NMM II B (23-40% compared to 82%) [154, 
196].  Both groups agree that NMM II B molecule has a higher duty ratio than NMM II A 
(3.8-11%) [154, 196].  Therefore it can be concluded that NMM II-B may be involved in 
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maintaining tonic force, while the faster NMM II-A may be involved in the rapid tension 
generation [186].  
1.3.4 Hepatic Stellate Cells and Myosin II 
HSCs play a critical role in liver microcirculation and fibrosis; therefore, it is 
important to understand the molecular aspects governing HSC contractility, proliferation 
and migration in response to injury.  HSCs express myosin II and actin and it has been 
suggested that this actomyosin complex regulates contraction much like it would in a 
smooth muscle cell [134, 136, 148, 197-200]. However in contrast to smooth muscle 
cells, HSCs favor a calcium-independent pathway mediated by RhoA [127, 198]. In order 
to characterize the role of myosin II in the HSC, pharmalogical agents, Y-27632 and 
blebbistatin, have been shown to inhibit myosin II phosphorylation [45, 134]. HSCs 
express a large number of early and late smooth muscle cell markers including smooth 
muscle (SM) !-actin, SM22!, desmin, SM myosin heavy chain, h1-calponin, h-
caldesmon and myocardin. Therefore, the smooth muscle myosin II proteins may play a 
role in HSC contraction [201]. Since the HSC is a nonmuscle cell, it is also possible that 
HSCs express NMM II to modulate the contractile apparatus; however, the specific 
myosin II classes or isoforms have not been characterized nor been correlated to a 
specific biological function in the HSC.  
1.4 HYPOTHESIS 
We hypothesize that hypercontraction, migration and proliferation of activated hepatic 
stellate cells (HSCs) are modulated by specific nonmuscle myosin II (NMM II) isoforms. 
Since the HSCs play a critical role in regulating liver microcirculation and the wound 
healing response during liver injury, determining the expression profile and function of 
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each NMM II isoform and delineating the mechanism of isoform induced expression in 
the HSC may lead to the development of specific-targeted therapeutics to treat the 
complications of portal hypertension seen in liver injury. 
Aims 
1. To test if directly inhibiting myosin II activity with blebbistatin can modulate 
HSC contraction. 
2. Determine the expression and cellular localization of the NMM II isoforms (II-A, 
II-B and II-C) in HSCs. 
3. To test if  gene knockdown of NMM II isoforms (II-A, II-B and II-C) can 
modulate contraction, migration and proliferation of HSCs.  
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FIGURE 1.1: Schematic Drawing of Normal Liver Architecture. The liver is the largest 
internal organ; it is smooth in texture and bright red in color. The hepatocyte is the 
primary cell type of the liver and the SECs line the blood vessel wall. The HSCs reside in 
the Space of Disse and the Kupffer cells are the resident macrophages. (Adapted from 
Friedman SL 2000) 
 
 
 
 
FIGURE 1.2: Schematic Drawing of Hepatic Lobule. The functional unit of the liver is 
the hepatic lobule. The liver receives 75% deoxygenated blood from the portal venous 
system and 25% oxygen rich blood from the hepatic arterial system. Hepatocytes 
optimize filtration, remove toxins from the microcirculation and excrete waste through 
the bile duct. Filtered blood drains through the central vein and exits the liver through the 
portal vein. (Adapted from Ross et al. 1995) 
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FIGURE 1.3: Schematic Drawing of Injured Liver. The injured liver is characterized by 
nodular formation and necrosis. Hepatocytes lose microvilli and Kupffer cells activate an 
inflammatory response. The SECs reduce blood filtration by closing fenestra and the 
HSCs excrete excessive collagen for matrix repair. (Adapted from Friedman SL 2000) 
 
 
FIGURE 1.4: Schematic Drawing of Injured Liver Mechanical Distortion. Increased scar 
matrix deposition contributes to mechanical distortion of the hepatic microvasculature. 
Additionally, hypercontractility of the HSCs increases vascular resistance in the sinusoids 
further compounding the clinical manifestation of portal hypertension. (Adapted from 
Rockey et al. 2003) 
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FIGURE 1.5: Hepatic Zonal Architecture. Functionally, the liver can be divided into 
three zones, based upon oxygen supply. Zone 1, the periportal triad region, is located 
around the portal tract where oxygenated blood from the hepatic artery enters. This 
region is susceptible to primary biliary disease. Zone 3, the pericentral region, is located 
around the central vein, where oxygen supply is low. This region is the most oxygen 
depleted and alcoholic liver fibrosis. (Adapted from The Internet Pathology Laboratory 
for Medical Education: The University of Utah Eccles Health Sciences Library) 
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FIGURE 1.6: Liver Transplant Statistics (1998-2007). Number of liver transplantations 
and size of waiting list per year. In 2002, the number of patients awaiting liver 
transplantation peaked and the gap between the waiting list and liver transplantation has 
decreased. (2008 U.S. Organ Procurement and Transplantation Network and the 
Scientific Registry of Transplant Recipients Annual Report) 
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FIGURE 1.7: Schematic Drawing of HSC Transdifferentiation. Quiescent HSCs store 
vitamin A in the form of retinoid droplets. Upon exposure to a damaging stimulus, the 
HSC undergoes a phenotypic change from the quiescent state to the activated 
myofibroblast-like state. Activated HSCs migrate to the site of injury, proliferate 
vigorously, become hypercontractile, secrete collagen and produce numerous cytokines 
and growth factors, which provide an environment appropriate for tissue repair. (Adapted 
from Brenner 1999) 
 
 
 
 
 
FIGURE 1.8: Representative Images of Quiescent HSCs in vitro. Quiescent HSCs are a 
star-like structure capable of modulating vascular tone. Lipophillic compounds exhibit 
characteristic blue autofluorescence measured with a DAPI (4',6-diamidino-2-
phenylindole) filter (~328nm $). 
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FIGURE 1.9: Schematic Drawing of ET-1-Induced Contraction in HSCs. ET-1 signals 
predominately through the ROCK signaling pathway resulting in phosphorylation and 
activation of myosin II promoting myosin II-generated contractile force in HSCs.   
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FIGURE 1.10: Schematic Drawing of HSC Proliferation/ Migration. Activation of 
several intracellular signaling pathways, including PDGF stimulation and FAK 
activation, lead to increased cell survival and proliferation of HSCs. 
 
 
 
 
 
FIGURE 1.11: Schematic Drawing of Myosin II. The myosin II molecule is composed of 
two MHCs (green) and two pairs of MLCs (blue). The MHC consists of the C-terminal 
dimerized tail region, which polymerize hundreds of myosin molecules in thick filaments 
of skeletal muscle cells, or as few as 28 myosins in nonmuscle cells and the N-terminal 
catalytic head domain, which contains a nucleotide-binding region and attaches to the 
actin filament. Phosphorylation of the MLC in the neck region releases the myosin 
molecular and stimulates actin dissociation. (©2002 From Molecular Biology of the Cell, 
4E by Alberts et al. Reproduced by permission of Garland Science/Taylor and Francis 
LLC.)
 
CHAPTER 2: GENERAL MATERIALS AND METHODS 
 
 
2.1 CELL CULTURE 
2.1.1 Materials 
Dulbecco's Modified Eagle Medium (DMEM) was purchased from Sigma Aldrich 
(St. Louis, MO). Fetal bovine serum (FBS) was purchased from Atlanta Biologicals 
(Lawrenceville, GA). HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) was 
purchased from EMD Chemicals Inc (Gibbstown, NJ). PSF (100 units penicillin/ml, 0.1 
mg/ml streptomycin and 0.25 g/ml amphotericin B), L-Glutamine-200 mM, PSG (100 
units penicillin/ml, 0.1 mg/ml streptomycin and 29.2 mg/ml L-Glutamine), sodium 
bicarbonate (NaHCO3) and phosphate buffered saline (PBS) were all purchased from 
Meditech (Hendon, VA). Rat-1 fibroblasts were purchased from American Type Culture 
Collection (ATCC; Manassas, Virginia). The human hepatic stellate cell (HSC) line, LX-
2, was provided by the laboratory of Dr. Scott Friedman (Mt. Sinai Medical Center; New 
York, NY). Trypan blue solution and trypsin-ethylenediaminetetraacetic acid (trypsin-
EDTA; 0.25% (v/v)) were purchased from Invitrogen (Gibco; Carlsbad, CA). A bright 
line counting chamber/hemocytometer was purchased from Hausser Scientific (Horsham, 
PA). Polystyrene bottles with 0.22 µM and molecular grade dimethyl sulphoxide 
(DMSO) were purchased from Fisher Scientific (Pittsburg, PA).
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Sterile tissue culture dishes and serological pipettes were purchased from Griener Bio-
One Inc (Monroe, NC). Chamber slides were purchased from Lab-Tek (Rochester, NY). 
5810R Centrifuge was purchased from Eppendorf (Olympus USA). 
2.1.2 Media Preparation 
All media was prepared under sterile conditions in a LABCONCO Purifier Class 
II Biosafety Cabinet. DMEM powder (13.4 g/l) was reconstituted in deionized water 
with 3.7 g/l NaHCO3, 5.95 g HEPES, pH 7.35 and sterilized using polystyrene bottles 
with 0.22 µM filters. Primary HSCs and LX-2 cells were cultured on plastic tissue culture 
dishes (p60/p100) or chamber slides with DMEM supplemented with 10% FBS, 1X PSF 
and 2 mM glutamine. Rat-1 fibroblasts were cultured on plastic tissue culture dishes 
(p100) with DMEM supplemented with 10% FBS and 1X PSG. Growth media was 
exchanged every other day unless otherwise noted. Serum-free media lacked FBS 
supplementation. All cells were cultured in a 5% CO2-95% air atmosphere at 37 ºC. 
2.1.3 Cell Propagation 
Cell lines were stored in cryovials submerged in liquid nitrogen. Vials were thawed 
in a 37ºC water bath and resuspended in culture media (10 ml). Cells were centrifuged at 
500 g for 3 minutes. Media was aspirated and the pellet was resuspended in 10 ml media. 
Cells were placed on a tissue culture dish and grown to 90% confluency in a 5% CO2-
95% air atmosphere at 37ºC. 
2.1.4 Cell Passaging and Splitting 
Primary HSCs, Rat-1 fibroblasts and human LX-2 cells were passaged until 
confluent (HSCs; p100 (7 days), p60 (4 days)). The cells were washed 3X in PBS and 
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detached using 0.25% (v/v) trypsin-EDTA diluted in PBS for 7 minutes at 37ºC. The 
addition of culture media inhibited further trypsin digestion after cells were detached from 
tissue culture dishes. Cells were pelleted at 500 g for 5 minutes and resuspended in 
culture media. A split ratio of 1:4 was used for passaging HSCs in tissue culture dishes 
(p100); 1:2 was used for p60 tissue culture dishes. A split ratio of 1:10 was used for 
passaging Rat-1 fibroblasts on tissue culture dishes (p100). A split ratio of 1:2 was used 
for passaging human LX-2 cells on tissue culture dishes (p100). 
2.1.5 Cell Storage 
Cell lines cells were washed 3X in PBS, trypsinized for 5 minutes and pelleted at 
500 g for 5 minutes and resuspended in cell freezing media (70% DMEM, 10% DMSO 
and 20% FBS). Suspensions were aliquoted at a concentration of 1 x 106 cells/ml into 
cryovials. The vials were stored at -80ºC overnight and submerged into liquid nitrogen for 
long term storage. 
2.2 PRIMARY CELL ISOLATION 
2.2.1 Materials 
Primary Isolation General Materials: Male Sprague-Dawley rats (190-200g; 
hepatocyte isolation and >650g; hepatic stellate cell (HSC) isolation) were purchased 
from Charles River Laboratory Inc (Wilmington, MA) and housed in the University 
Vivarium. 5810R Centrifuge was purchased from Eppendorf (Olympus USA). 
Polystyrene bottles with 0.22 µM filters and Nalgene 50ml conical tube filter units were 
purchased from Fisher Scientific (Pittsburg, PA). Tissue culture dishes (p60 and p100) 
and conical tubes (15 and 50 ml) were purchased from BD Biosciences (San Diego, CA). 
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PSF (100 units penicillin/ml, 0.1 mg/ml streptomycin and 0.25 !g/ml amphotericin B) 
was purchased from Meditech (Hendon, VA). Deoxyribonuclease I (DNase) and Type I 
collagenase were purchased from Sigma Aldrich (St. Louis, MO). DNase (10 mg/ml) was 
reconstituted in deionized water and sterilized using syringe filters (0.45 µM) purchased 
from Corning Inc (Corning, NY). 
Primary HSC Isolation Protocols: Multiple strategies were employed to isolate a pure 
(95%) population of primary HSCs. The protocol was altered three times to optimize cell 
number and to eliminate fungal/bacterial contamination. Pronase was purchased from 
Roche Applied Sciences (Chicago, IL).  
Protocol A: Spinner Modification Minimum Essential Medium (SMEM) was 
purchased from Sigma Aldrich (St. Louis, MO). Gey's Balanced Salt Solution (GBSS) was 
freshly prepared with salts/glucose purchased from Fisher Scientific (Pittsburg, PA; 
TABLE 2.1A), pH 7.35 and sterile filtered.  
GBSS g/l 
NaCl 8 
KCl 0.4 
KH2PO4
 
 0.05 
NaH2PO4
 
 0.15 
MgCl2-6H2O 0.21 
MgSO4-7
 
H2O 0.07 
CaCl2
 
 0.23 
Glucose  2 
 
 
TABLE 2.0A: GBSS Buffer Protocol A. GBSS buffer was freshly prepared each 
week for HSC isolation. Salts were reconstituted in 4 liters of deionized water, pH 
7.35 and sterile filtered. 
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Pronase and collagenase were reconstituted in pre-warmed GBSS (46ºC). Density 
gradients were prepared from Larcoll (Sigma Aldrich) reconstituted in freshly prepared 
BSG-BSA solution (1.22 mg/ml Na2HPO4, 0.169 mg/ml NaH2PO4, 7.2 mg/ml NaCl, 0.373 
mg/ml KCl, 0.116 mg/ml MgCl2, 2 mg/ml glucose, and 30 mg/ml Bovine Serum Albumin 
(BSA)), pH 7.35 and sterile filtered. Portable refractometer was purchased from Fisher 
Scientific. Optima L-90K UltraCentrifuge and Ultra-clear centrifuge tubes (9/16 x 3 " in) 
were purchased from Beckman Coulter Inc (Fullerton, CA).  
Protocol B: SC-1, SC-2, GBSS/A and GBSS/B solutions were freshly prepared 
with salts purchased from Fisher Scientific (TABLE 2.1B), pH 7.35 and sterile filtered. 
Ethylene glycol-bis(2-aminoethylether)-N,N,N!,N!-tetraacetic acid (EGTA) was 
purchased from Sigma Aldrich.  
g/l SC-1 SC-2 GBSS/A GBSS/B 
NaCl 80 80 (-) 80 
KCl 4 4 3.7 3.7 
NaH2PO4 0.88 0.88 (-) (-) 
Na2HPO4 1.2 1.2 0.59 0.59 
HEPES 23.8 23.8 (-) (-) 
NaHCO3 3.5 3.5 (-) (-) 
EGTA 1.9 (-) (-) (-) 
Glucose 9 (-) 9.91 9.91 
CaCl2 (-) 5.6 2.25 2.25 
MgCl2-6H2O (-) (-) 2.1 2.1 
MgSO4-7 H2O (-) (-) 0.7 0.7 
K2HPO4 (-) (-) 0.3 0.3 
 
 
 
TABLE 2.1B: Isolation Buffers Protocol B. Isolation buffers were freshly 
prepared each week for HSC isolation. Salts were reconstituted in 4 liters of 
deionized water, pH 7.35 and sterile filtered. 
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Pronase and collagenase were reconstituted in pre-warmed SC-2 (37ºC). Density gradients 
were prepared from Histodenz (Sigma Aldrich) reconstituted in GBSS/A (290 mg/ml) and 
sterile filtered. 
Protocol C: Buffer A solution and GBSS were freshly prepared with salts 
purchased from EMD Chemicals Inc (Gibbstown, NJ), EGTA purchased from Sigma 
Aldrich and glucose purchased from Fisher Scientific (TABLE 2.1C), pH 7.35 and sterile 
filtered.  
g/l Buffer A GBSS 
NaCl 6.7 7 
KCl 0.37 0.37 
NaH2PO4 (-) 0.15 
HEPES 5.95 5.95 
NaHCO3 (-) 2.27 
EGTA 0.2 (-) 
Glucose (-) 1 
CaCl2 (-) 0.22 
MgCl2-6H2O (-) 0.21 
MgSO4-7 H2O (-) 0.07 
KH2PO4 0.136 0.03 
 
Pronase and collagenase were reconstituted in pre-warmed GBSS (42.5ºC). Density 
gradients were prepared from Optiprep (Axis-Shield; Oslo, Norway) reconstituted in 
GBSS and sterile filtered: 66.7 ml OptiPrep (60%) stock solution + 33.3 ml GBSS= 40% 
(v/v) OptiPrep working solution.  
TABLE 2.1C: Isolation buffers were freshly prepared each week for HSC 
isolation (Protocol C). Salts were reconstituted in 4 liters of deionized water, pH 
7.35 and sterile filtered. 
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Primary Hepatocyte Isolation Protocol: Buffer A, Buffer B and Buffer C solutions were 
freshly prepared with salts purchased from EMD Chemicals Inc, BSA purchased from 
and EGTA purchased from Sigma Aldrich (TABLE 2.2), pH 7.35 and sterile filtered.  
g/l Buffer A   Buffer B  Buffer C 
NaCl 6.7 6.7 6.7 
KCl 0.37 0.37 0.37 
KH2PO4 0.136 0.136 0.136 
HEPES 5.95 5.95 5.95 
EGTA 1.9 (-)  (-) 
 BSA (-)  (-) 6 
CaCl2 (-) 0.0184 0.0368 
 
Collagenase was resuspended in pre-warmed Buffer B and Buffer C (42.5ºC). 
2.2.2 Hepatic Stellate Cell Isolation 
Primary Isolation General Methods: In all procedures retired breeder male 
Sprague-Dawley rats were used under appropriate anesthesia and aseptic conditions. 
Breathing pattern and conscious level were used to monitor animal’s anesthesia. Prior to 
the procedure, all surgical instruments were sterilized by autoclaving. The skin was 
shaved and disinfected with Betadine and 75% (v/v) ethanol. A midline laparotomy on the 
rat abdomen was performed, and the hepatic portal vein and vena cava were dissected out. 
Heparin (500U) was injected into the vena cava to alleviate red blood cell clotting and 
permit perfusion of liver. The portal vein was cannulated with SURFLO I.V. catheter 
proximal to bifurcation, attached with 3-0 (USP) silk suture, and the descending aorta was 
TABLE 2.2: Isolation buffers were freshly prepared for hepatocyte isolations. 
Salts were reconstituted in 1 liter of deionized water, pH 7.35 and sterile filtered. 
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immediately cut to allow exsanguination. Cell purity was measured by morphology and 
autofluorescence. 
Protocol A: Density gradients (%=1.045 and 1.035) were prepared using 20% 
(w/v) Larcoll in BSG-BSA solution and sterile filtered. Approximately, 1.045(%)=42.9 ml 
20% Larcoll solution + 57.1 ml BSG-BSA; 1.035(%)=29.1 ml 20% Larcoll solution + 70.9 
ml BSG-BSA. A portable refractometer was used to determine accurate density readings 
(1.045: refractometer reading=8.1; 1.035: refractometer reading=5.5) Perfusion, pronase, 
collagenase, agitation and washing buffers were also prepared prior to surgery (TABLE 
2.3A). 
  Perfusion Pronase Collagenase Agitation Washing 
SMEM 200 ml (-) (-) (-) (-) 
GBSS (-) 100 ml 200 ml 100 ml 200 ml 
Pronase (-) 0.4 %b.w. (-) (-) (-) 
Collagenase (-) (-) 25-30 mg (-) (-) 
DNase (-) (-) (-) 100 µl 200 µl 
PSF 2 ml 1 ml 2 ml 1 ml 2 ml 
 
Retired breeder male Sprague-Dawley rats (>650 g) were injected with sodium 
pentobarbital (50 mg/kg) subcutaneously and pre-warmed buffers pumped through the 
liver at a rate of 15 ml/min. The liver was initially perfused with perfusion buffer for 10 
minutes and then switched to pronase buffer. After collagenase digestion, the liver was 
excised, placed in tissue culture dish, minced and washed in a 500 ml beaker with agitation 
buffer. The solution was agitated at 120 RPM for 10 minutes in 37 ºC water bath. In the 
TABLE 2.3A: Isolation buffers were freshly prepared for each HSC isolation with 
SMEM and GBSS (TABLE 2.1A). Collagenase buffer was sterile filtered. 
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tissue culture hood, two conical tubes (50 ml) were overlaid with sterile gauze filters. The 
liver homogenate was filtered into the tubes and centrifuged for 2 minutes at 50 g at 25ºC. 
The pellet was washed 2X. The pellet was resuspended and centrifuged for 7 minutes at 
700 g at 25ºC. The density gradients were prepared in UltraClear tubes (1.035/1.045; 2.5 
ml each). The pellet was resuspended in washing buffer and layered on top of density 
gradient (7 ml/tube). The tubes were placed in the Optima L-90K UltraCentrifuge and 
centrifuged for 35 minutes at 22,000 RPM at 20ºC with break set to 800 RPM. A distinct 
HSC layer and HSC/Kupffer cell (KC) layer were transferred to two conical centrifuge 
tubes (50 ml) and washed (FIGURE 2.1). The suspension was centrifuged for 7 minutes 
at 700 g at 25ºC. The pellet was resuspended in 1 ml HSC media and 20 µl of the cell 
suspension was diluted (10X) and counted with a hemocytometer. Cell viability was 
measured by the total number of trypan blue stained (dead) vs. live cells: (Total number) 
x (viability) = Total number of live cells/ml. For quiescent HSCs, only the pure layer was 
used for experiments. For culture-activated HSCs, the pure layer was combined with 
HSC/KC layer (3x106 cells/p100) to optimize cells number. The culture media does not 
support KC viability. On average, 10-12 x106 cells were obtained using this protocol.  
Protocol B: Due to ultracentrifuge scheduling conflicts and economic benefits, our 
lab developed a new protocol for HSC isolation that did not require the use of the Optima 
L-90K UltraCentrifuge. To increase cell numbers per isolation we also optimized the 
buffers used and perfusion apparatus. Changes to Protocol A included decreasing pronase 
and increasing collagenase concentration, changing anesthetic method, buffer solutions and 
density gradients. Density gradient was prepared using Histodenz solution and sterilized 
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using 0.22 µM filter. Perfusion, pronase, collagenase, agitation and washing buffers were 
also prepared prior to surgery (TABLE 2.3B). 
  Perfusion Pronase Collagenase Agitation Washing 
SC-1 200 ml (-) (-) (-) (-) 
SC-2 (-) 120 ml 250 ml 120 ml (-) 
GBSS/B (-) (-) (-) (-) 200 ml 
Pronase (-) 80 mg (-) (-) (-) 
Collagenase (-) (-) 80 mg (-) (-) 
DNase (-) (-) (-) 100 µl 200 µl 
PSF 2 ml 1 ml 2 ml 1 ml 2 ml 
 
Retired breeder male Sprague-Dawley rats (>650 g) were anesthetized using isoflurane 
inhalation (2-5%) and liver perfused as previously described. In the tissue culture hood, 
four conical tubes (50 ml) were capped with nylon mesh sheets (120 µM). The liver 
homogenate was filtered into the tubes and centrifuged for 8 minutes at 500 g at 4ºC. The 
pellet was washed (washing buffer) and re-centrifuged. The pellet was resuspended in 
washing buffer (34 ml/ tube) and combined with Histodenz solution (14 ml/ tube). The 
liver homogenate/density gradient mixture (12 ml/tube) was transferred to 15 ml conical 
tubes and washing buffer (1 ml) was layered onto the solution. The tubes were placed in 
the Eppendorf 5810R Centrifuge and spun for 17 minutes at 2500 RPM at 4ºC with no 
break. A distinct HSC layer was visible and transferred to a conical centrifuge tube (50 
ml) and washed (FIGURE 2.2). The suspension was centrifuged for 7 minutes at 700 g at 
4ºC. Cells were counted and viability measured as previously described. On average, 15-
20 x106 cells were obtained using this protocol. 
TABLE 2.3B: Isolation buffers were freshly prepared for each HSC isolation with 
Buffer A and GBSS (TABLE 2.1B). Collagenase buffer was sterile filtered. 
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Protocol C: After five months of contamination and low cellular yield, our lab 
changed the protocol used for HSC isolation. Changes to Protocol A included altering the 
buffer and density gradient solutions. Density gradients were prepared using 40% (w/v) 
Optiprep solution and sterile filtered. Perfusion, pronase, collagenase, agitation and 
washing buffers were also prepared prior to surgery (TABLE 2.3C). 
  Perfusion Pronase Collagenase Agitation Washing 
Buffer A 250 ml (-) (-) (-) (-) 
GBSS (-) 100 ml 200 ml 125 ml 200 ml 
Pronase (-) 80 mg (-) (-) (-) 
Collagenase (-) (-) 25-30 mg (-) (-) 
DNase (-) (-) (-) 125 µl 200 µl 
PSF 2.5 ml 1 ml 2 ml 1 ml 2 ml 
 
Retired breeder male Sprague-Dawley rats (>650 g) were anesthetized using isoflurane 
inhalation (2-5%) and liver perfused as previously described. In the tissue culture hood, 
four conical tubes (50 ml) were capped with sterile gauze. The liver homogenate was 
filtered into the tubes and centrifuged for 7 minutes at 700 g at 4ºC. The pellet was 
washed and re-centrifuged for 7 minutes at 700 g at 4ºC. The pellet was resuspended in 
washing buffer (37.8 ml/tube) and combined with 40% Optiprep solution (10.2 ml/tube). 
The liver homogenate/density gradient mixture (12 ml/tube) was transferred to 15 ml 
conical tubes and washing buffer (2 ml) was layered onto the solution. The tubes were 
centrifuged for 17 minutes at 1400 g at 4ºC with no break. A distinct HSC layer was 
visible (similar to Protocol B), transferred to a conical tube (50 ml) and washed. The 
TABLE 2.3C: Isolation buffers were freshly prepared for each HSC isolation with 
Buffer A and GBSS (TABLE 2.1C). Collagenase buffer was sterile filtered. 
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suspension was centrifuged for 7 minutes at 700 g at 4ºC. Cells were counted and 
viability measured as previously described. On average, 20-30 x106 cells were obtained 
using this protocol.  
2.2.3 Hepatocyte Isolation 
The HSC isolation method (Protocol C) was used to isolated hepatocytes with 
minor revisions. In all procedures retired breeder male Sprague-Dawley rats (190-200 g) 
were used and surgeries performed as described for HSC isolation. Changes to Protocol C 
included omitting of the pronase solution and changing the perfusion and collagenase 
buffer. Perfusion, collagenase and agitation/washing buffer were all prepared prior to 
surgery (TABLE 2.4). 
  Perfusion Collagenase Agitation/ Washing 
Buffer A 250 ml (-) (-) 
Buffer B (-) 200 ml (-) 
Buffer C (-) (-) 500 ml 
Collagenase (-) 30 mg (-) 
DNase (-) (-) 500 µl 
PSF 2.5 ml 2 ml 5 ml 
 
In the tissue culture hood, four conical tubes (50 ml) were capped with sterile mesh filter 
(150 µm pore diameter). The liver homogenate was filtered into the tubes and centrifuged 
for 3 minutes at 50 g at 25ºC. The pellet was washed and re-centrifuged for 3 minutes at 
50 g at 25ºC. Cells were counted and viability measured as previously described.  
2.3 ANIMAL MODEL OF LIVER FIBROSIS 
TABLE 2.4: Isolation buffers were freshly prepared for each hepatocyte isolation 
with Buffer A/B/C (TABLE 2.2). Collagenase buffer was sterile filtered. 
. 
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2.3.1 Materials 
Male Sprague-Dawley rats (350-450 g) were purchased from Charles River 
Laboratory Inc (Wilmington, MA) and housed in the University Vivarium. Black 3-0 
(USP) silk and nylon sutures were purchased from LOOK Surgical Specialties 
Corporation (Reading, PA). TissuePrep paraffin based embedding media, xylene, 
HistoPrep tissue capsules and Superfrost plus microscope slides were purchased from 
Fisher Scientific (Pittsburgh, PA). 10% (w/v) formalin solution was purchased from 
Sigma Aldrich (St Louis, MO). Phosphate buffered saline (PBS) was purchased from 
Meditech (Hendon, VA). Hematoxylin and eosin were purchased from EMD Chemicals 
Inc (Gibbstown, NJ). HM 315 rotary microtome was purchased from Richard-Allan 
Scientific (Kalamazoo, MI). ATP1 automatic tissue processor was purchased from 
Triangle Biomedical Sciences Inc. (Durham, NC). Hematoxylin and eosin staining was 
visualized with an Olympus IX71 microscope and Fluoview FV500 version 4.3 image 
processing software (Olympus USA). 
2.3.2 Bile Duct Ligation Surgery 
Animal model of bile duct ligation (BDL) induced-fibrosis: 30 minutes prior to 
procedure, animals were injected with buprenophrine (0.05 mg/kg) subcutaneously. Prior 
to the procedure, all the surgical instruments were sterilized by autoclaving. Under 
isoflurane anesthesia (2-5% by inhalation), the skin was shaved and disinfected with 
Betadine and 75% ethanol. Breathing pattern and conscious level were used to monitor 
animal’s depth of anesthesia. A midline laparotomy on the rat abdomen was performed 
and the hepatic bile duct identified, double-ligated with silk suture and transected. The 
abdomen was closed by continuous pattern using absorbable sutures approved by the 
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attending veterinarian. The skin was closed using non-absorbable sutures in an 
interrupted pattern. Sham operations were performed in the same manner except without 
BDL. The animals were injected with buprenophrine every 8-12 hours for the first 48 
hours or until animal was alert, active and eating a minimum of two pellets of chow per 
day. Animals were followed for 14 days and sacrificed by exsanguination under 
anesthesia for tissue sample processing.  
2.3.3 Tissue Preparation 
Liver tissue samples were harvested and fixed in formalin solution overnight at 
room temperature. Formalin solution was replaced with 50% (v/v) ethanol for 1 hour 
followed by final storage in 50 ml conical tube of 70% (v/v) ethanol. Cells were 
dehydrated in ascending ethanol gradient (50%, 70%, 80%, 95% and 100%) for 10 
minutes each and blocked in paraffin in an automatic tissue processor. 5 µM sections 
were cut using HM 315 rotary microtome and adhered onto positively charged glass 
slides. Sections were dried at 37ºC on a slide warmer and stored at room temperature. 
2.3.4 Hematoxylin and Eosin Staining 
 
Slides were incubated at 65
o
C for 1 hour, submerged in xylene for 5 minutes and 
rehydrated using descending ethanol gradient (100%, 90%, 80%, 70%, and 60%) for 10 
minutes each with a final wash in PBS for 5 minutes. Slides were incubated in 
hematoxylin solution for 5 minutes and rinsed in tap water before staining with eosin 
solution for 10 seconds. After eosin staining, slides were dehydrated into descending 
grades of ethanol (100%, 95%, 80%, 70% and 50%) followed by xylene incubation for 
10 seconds. Slides were mounted and coverslipped using Permount mounting media. 
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Images were captured with IX71 microscope and Fluoview FV500 version 4.3 image 
processing software.  
2.4 CONTRACTION ASSAY 
2.4.1 Materials 
Rat tail type I collagen, prepared in 0.02N Acetic Acid (3.65-4.5 mg/ml), was purchased 
from BD Biosciences (Bedford, MA). Dulbecco's Modified Eagle Medium (DMEM) 
purchased from Sigma Aldrich (St. Louis, MO), HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) purchased from EMD Chemicals Inc (Gibbstown, NJ) and 
sodium bicarbonate purchased from Fisher Scientific (Pittsburgh, PA) were reconstituted 
into a 10X solution. Acetic acid and molecular grade dimethyl sulphoxide (DMSO) were 
purchased from Fisher Scientific. Sterile 24-well tissue culture plates were purchased 
from Griener Bio-One Inc (Monroe, NC). Bovine serum albumin (BSA) purchased from 
Roche Applied Sciences (Chicago, IL) was reconstituted in phosphate buffered saline 
(PBS) purchased from Meditech (Hendon, VA). Endothelin-1 (ET-1) was purchased from 
American Peptide (Sunnyvale, CA) and reconstituted in sterile deionized water. 
Blebbistatin was purchased from Calbiochem (San Diego, CA) and reconstituted in 
DMSO. BioSpectrum AC Imagining System and ImageMaster program purchased from 
UVP Inc (Upland, CA) was used to measure changes in collagen lattice diameter over 
time. 
2.4.2 Collagen Lattice Preparation 
Collagen lattices were prepared as previously described with minor modifications 
[14, 32]. 24-well tissue culture plates were incubated with 0.1% (w/v) BSA and washed 
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3X for 5 minutes with PBS. A combination of 8 parts type I collagen, 1 part 0.2 M 
HEPES and 1 part 10X DMEM (optimal collagen concentration experimentally 
determined to be 3.65 mg/ml) was mixed at room temperature. The mixture (optimal 
volume experimentally determined to be 300 µl) was aliquoted onto each well of a 24-well 
plate and allowed to congeal for 1 hour at 37°C.  
2.4.3 Hepatic Stellate Cell Seeding 
Primary HSCs (5 x 106 cells/p60) were cultured to confluency (3 days) and 
incubated in serum-free DMEM overnight. Day 4 culture-activated HSCs were 
trypsinized and seeded onto the congealed collagen lattice (optimal cell number 
experimentally determined to be 300,000 cells/well diluted in 300 µl serum-free DMEM) 
and allowed to recover overnight in a 5% CO2-95% air atmosphere at 37°C. 
2.4.4 LX-2 Cell Seeding 
LX-2 cells were grown to confluency and incubated in serum-free DMEM 
overnight. LX-2 cells were trypsinized and seeded onto the congealed collagen lattice 
(300,000 cells/well) and allowed to recover overnight in a 5% CO2-95% air atmosphere at 
37°C.  
2.4.5 Chemical Treatment 
ET-1 Treatment: Serial dilutions of ET-1 (0.1 pM-100 nM; logarithmic 
increments) were prepared and incubated with HSC-seeded collagen lattices. Serum-free 
DMEM served as negative control. Collagen discs were dislodged from wells with a 10 µl 
pipette tip. LX-2 cells were treated with an experimentally determined ET-1 concentration 
(1 nM). Images were captured with UVP BioSpectrum AC Imagining System at indicated 
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time points and the PTI ImageMaster program was used to measure changes in collagen 
diameter after 24 hours. 
Blebbistatin Treatment: Wells were pre-treated with increasing doses of the 
blebbistatin active enantiomer or inactive enantiomer (5-25 #M; 5 #M increments) for 30 
minutes. Collagen discs were dislodged from wells with a 10 µl pipette tip and 
empirically determined ET-1 concentration (1 nM) was incubated with pre-treated cells 
to induce contraction. Serum-free DMEM served as positive control for ET-1 induced 
contraction. Images were captured with UVP BioSpectrum AC Imagining System at 
indicated time points and the PTI ImageMaster program was used to measure changes in 
collagen diameter over time. 
2.5 PREPARATION OF RNA and cDNA  
2.5.1 Materials  
Diethyl pyrocarbonate (DEPC)-treated water and agarose were purchased from 
EMD Chemicals Inc (Gibbstown, NJ). TRIzol reagent, SuperScript III Reverse 
Transcription System, random primers (3 µg/µl) and deoxynucleotide triphosphates 
(dNTPSs; reconstituted in DEPC-treated water; 20 nM) were purchased from Invitrogen 
(Carlsbad, CA). Chloroform, isopropanol and ethidium bromide were purchased from 
Fisher Scientific Inc (Pittsburg, PA). Maxwell 16 Total RNA Purification Kit, RQ1 
RNase-Free DNase Kit, Impromptu II Reverse Transcription System, 100 bp DNA 
ladder and blue/orange 6X loading dye were purchased from Promega Corporation 
(Madison, WI). Chloroform and isopropanol were purchased from Fisher Scientific. 
Sodium acetate solution (3 M) and Tris-acetate (TAE) buffer were purchased from 
Meditech (Hendon, VA). Microcentrifuge tubes were purchased from Griener Bio-One 
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Inc (Monroe, NC). 5415R Centrifuge was purchased from Eppendorf (Olympus USA). 
Gene Spectrophotometer (MiraiBio; San Francisco, CA) and NanoDrop (Fisher Scientific 
Inc) were used to quantitate RNA and cDNA concentrations.  
2.5.2 RNA Isolation 
 Total RNA from tissue (30 mg), Rat-1 fibroblasts, quiescent and culture-activated 
hepatic stellate cells (HSCs) were isolated using the TRIZOL method according to the 
manufacturer’s directions. Cells (2-5 x 106) were lysed in 1 ml of reagent and transferred 
to 1.5 ml micro-centrifuge tubes. Samples were incubated with 200 µl chloroform, 
vortexed and incubated at room temperature for 10 minutes to allow complete 
dissociation of nucleoprotein complexes. Samples were centrifuged at max speed (12,000 
g) at 4
o
C for 10 minutes. Following centrifugation, the mixture separated into a lower 
red, phenol/chloroform phase, a buffy white interphase and a clear upper aqueous phase. 
The aqueous phase was either transferred to a new 1.5 ml micro-centrifuge tube or Well 
#1 of the Maxwell 16 Total RNA Purification Kit. Samples transferred to new 1.5 ml 
micro-centrifuge tubes were incubated with 500 µl isopropanol to precipitate the RNA. 
Samples were centrifuged at max speed at 4
o
C for 10 minutes. The pellet was washed 
with 75% (v/v) ethanol and centrifuged at max speed. Final RNA was dissolved in 12-20 
µl DEPC-treated water, quantified with the Gene Spectrophotometer or the NanoDrop 
and stored at -80°C. Alternatively, samples transferred to Well # 1 of the Maxwell 16 
Total RNA Purification Kit were run on the LEV (low elution volume) program (Version 
3.31) and dissolved in 50 µl DEPC-treated water. RNA samples were diluted with 6X 
loading dye and run with 100 bp ladder on a 2% (w/v) agarose gel (dissolved in TAE 
buffer) stained with ethidium bromide to determine RNA integrity and purity.  
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2.5.3 cDNA Preparation 
RNA samples were DNase treated and reverse transcribed with Impromptu II or 
Superscript III according to the manufacture’s directions. Approximately 5-10 µg RNA 
was incubated with 1 µl of 10X RQ1 DNase buffer (400 mM Tris-HCl [pH 8.0 at 25°C], 
100 mM MgSO4, 10 mM CaCl2) and 1 µl of RQ1 DNase at 37
o
C. Stop Buffer (20 mM 
EGTA [pH 8.0 at 25°C]) was added after 30 minutes. Samples were incubated at 75oC for 
5 minutes, cooled to room temperature and combined with master mix from each protocol 
(TABLE 2.5). 
Impromptu II Protocol SuperScript III Protocol 
4 µl 5X Buffer 4 µl 5X Buffer 
2.5 µl MgCl2 1 µl 0.1 M DTT 
1 µl dNTPs 1 µl dNTPs 
1µl Random Primers 1µl Random Primers 
1 µl Reverse Transcriptase 1 µl Reverse Transcriptase 
 
Samples were incubated at 37
o
C for 90 minutes and the reverse transcriptase heat 
inactivated at 80
o
C for 5 minutes. To precipitate the cDNA, samples were incubated with 
2 µl sodium acetate and 300 µl 100% (w/v) ethanol. The mixture was incubated at -80oC 
overnight and centrifuged at max speed. Final cDNA pellet was dissolved in 50 µl 
DEPC-treated water, quantified
 
with the Gene Spectrophotometer or the NanoDrop and 
stored at -80°C. 
2.6 REVERSE TRANSCRIPTION-PCR AND REAL TIME PCR 
2.6.1 Materials 
TABLE 2.5: Master mix for cDNA transcription using Impromptu II or 
SuperScript II protocol. 
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Diethyl pyrocarbonate (DEPC)-treated water and agarose were purchased from 
EMD Chemicals Inc (Gibbstown, NJ).  GoTaq
 
Green Master Mix was purchased from 
Promega Corporation (Madison, WI). SYBR green 2X reaction mixture and capillary 
tubes were purchased from Roche Applied Sciences (Chicago, IL). TAE buffer was 
purchased from Meditech. Techne TC-512 (Techne Inc; Burlington, NJ) and Roche 
LightCycler 2.0 Instrument (Roche Applied Sciences) were used to amplify cDNA 
templates. Using the published GenBank sequence for Glyceraldehyde 3-phosphate 
dehydrogenase (Gapdh; NM_017008), smooth muscle !-actin (Acta2; NM_031004), 
glial acidic fibrillary protein (Gfap; NM_017009.2), nonmuscle myosin II-A (MYH9; 
NM_022410), II-B (MYH10; NM_031520) and II-C (MYH14; NM_028021), primers 
were generated with the OLIGO 6 program (TABLE 2.6) and purchased from Integrated 
DNA Technologies (Coralville, IA).  
Gene Forward (5’!3’) Reverse (3’!5’) Size (bp) 
Glyceraldehyde 3 Phosphate 
Dehydrogenase (Gapdh) 
ATCCCGCTAACATAC
CCTGG 
ACTGTGGTCATGA
GCCCTTC 
292 
Smooth Muscle !-Actin  
(Acta) 
CATCAGGAACCTCGA
GAAGC 
TCGGATACTTCAG
GGTCAGG 
247 
Glial Acidic Fibrillary Protein 
(Gfap) 
AGAAAACCGCATCA
CCATTC 
TTGGGCCTAGCA
AACAAGAC 
264 
Nonmuscle Myosin II A 
(Myh9) 
CCCTGCTAGATGAGG
AGTGC 
TGTTCTTCATCAG
CCACTCG 
189 
Nonmuscle Myosin II B 
(Myh10) 
GGCACTGGAGGAAC
TCTCTG 
CTTCTTCCAGCAG
GGTTGAG 
287 
Nonmuscle Myosin II C 
(Myh14) 
GCTGCTCAAGGACCA
TTACC 
GTACCAGCTTGCC
AGAGAGG 
275 
 
 
TABLE 2.6: Primers were generated using OLIGO 6 program and used in RT-
PCR and RealTime PCR analyses.  
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2.6.2 Reverse Transcription-PCR 
 The RT-PCR amplification reaction combined 1 µg cDNA with 25 µl GoTaq 
Green Master Mix, 20 µl DEPC-treated water, and 0.5 µg of each primer. PCR was 
performed with the Techne TC-512, using standard protocol: 52 to 57°C annealing step, 
for 20-45 cycles. Amplified products were resolved by electrophoresis in 2% (w/v) 
agarose gels and visualized by UV illumination.  
2.6.3 RealTime-PCR 
 RealTime PCR amplification reactions were performed using the Roche 
LightCycler 2.0 instrument. The reaction combined 1 µl of cDNA, 5 µl SYBR green 2X 
reaction mixture, 1 µl of each primer (5 µM), and 2 µl DEPC-treated water in a 20 µl 
capillary tubes. All samples underwent 40 cycles at the determined annealing 
temperature. A reference pair of PCR products was generated in order to quantitate the 
message in the samples. The sample products were electrophoresied on a 2% (w/v) 
agarose gel to ensure a distinct product. 
 Data was reported as cross-point, the point at, which the SYBR green 
fluorescence was detected above the background [202]. Minor modifications were made 
by subtracting the cross-point from the largest adjusted cross-point (&CP) in the gene set 
and normalized to total cDNA concentration. 
2.7 PREPARATION OF PROTEIN LYSATES 
2.7.1 Materials 
Radioimmunoprecipitation assay (RIPA) buffer (1X lysis buffer, PMSF, protease 
inhibitor cocktail and sodium orthovanadate) was purchased from Santa Cruz 
Biotechnology Inc (Santa Cruz, CA). Tris-base was purchased from BioSpectra Inc 
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(Stroudsburg, PA).  F-actin (105-120 µM) stock was freshly prepared by in Dr. Chris 
Yengo’s laboratory (University of North Carolina at Charlotte). Bradford protein assay 
was purchased from Pierce Biotechnology (Rockford, IL). Bovine serum albumin (BSA) 
was purchased from Roche Applied Sciences (Chicago, IL). Sodium dodecyl sulfate 
(SDS), bromophenol blue, glycerol and 2-mercaptoethanol (BME) were purchased from 
Fisher Scientific (Pittsburg, PA). Laemmli buffer (2X; 4% (w/v) SDS, 20% (w/v) 
glycerol, 10% (w/v) 2-mercaptoethanol, 0.004% (w/v) bromphenol blue, 0.125 M Tris-
HCl) was prepared in deionized water. Semi-microcuvettes were purchased from BioRad 
Laboratories (Hercules, CA). Sonfier 150 homogenizer was purchased from Branson 
Ultrasonic Corporation (Danbury, CT). Optima TLX120 Ultracentrifuge and DU640 
scanning spectrophotometer were purchased from Beckman Coulter Inc (Fullerton, CA). 
5415R Centrifuge was purchased from Eppendorf (Olympus USA).  
2.7.2 Bradford Protein Assay 
Protein concentrations were determined using the Bradford method. Protein 
standards (0-12 µg/ml) were prepared using BSA (1 mg/ml) diluted in RIPA buffer. 
Standards and lysates were assayed using DU640 scanning spectrophotometer. Working 
protein assay solution was prepared by diluting Bradford reagent in deionized water (1:5; 
1 ml/sample) and solution added to semi-microcuvettes (both standards and lysates). 
Absorbance at 595 nM was measured with the spectrophotometer. Absorbance for each 
standard was corrected for mean zero standard absorbance and plotted against protein 
concentration (mg/ml). The resulting standard curve was used to determine protein 
concentration of unknown samples. 
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2.7.3 Preparation of Cell Lysates for Protein Analysis 
Quiescent and culture-activated hepatic stellate cells (HSCs) and Rat-1 fibroblasts 
were sonicated in RIPA buffer at 4°C. Subsequently, lysates were centrifuged at 16,000 g 
for 5 minutes at 4°C and the supernatant subjected to precipitation by F-actin selection. 
Protein concentrations were
 
measured by the Bradford method (Section 2.7.2). For pull-
down experiments, the quiescent samples were diluted to 1 µg/µl of protein in RIPA 
buffer, while the remaining samples were diluted to 0.5 µg/µl and incubated with 10 µM 
F-actin stock at 4°C for 30 minutes. The complex was centrifuged at 320,000 g in an 
Optima TLX120 Ultracentrifuge for 30 minutes at 4°C. The pellet was resuspended in 50 
µl of 2X Laemmli buffer and stored at -80°C overnight.  
2.7.4 Preparation of Tissue Lysates for Protein Analysis 
Tissues were resected and immediately snap frozen in liquid nitrogen. To extract 
whole cell lysates, approximately 30 mg of tissue was placed in 1 ml RIPA buffer and 
homogenized in an ice bucket using the Sonifier 150 (level 5) 3-5 seconds and centrifuged 
at 16,000 g for 5 minutes at 4ºC. The resulting supernatant was collected, briefly 
resonicated and stored at -80ºC. Protein concentrations were
 
measured by the Bradford 
method (Section 2.7.2). 
2.8 WESTERN BLOTTING 
2.8.1 Materials 
Enhanced chemiluminescence (ECL) detection kit and CL-XPosure X-ray film 
were purchased from Pierce Biotechnology (Rockford, IL). Tris-base was purchased from 
BioSpectra Inc (Stroudsburg, PA).  Acrylamide solution (Acrylamide: Bis, 29:1 
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acrylamide/N,N’-ethylenebisacrylamide) and TEMED (N,N,N',N'-
Tetramethylethylenediamine) were purchased from EMD Chemicals Inc (Gibbstown, 
NJ). Ponceau S solution was purchased from Sigma Aldrich (St. Louis, MO). Sodium 
dodecyl sulfate (SDS), ammonium persulfate (APS; 10% (w/v) solution reconstituted in 
deionized water), Tween-20, sodium chloride (NaCl) and 2-mercaptoethanol (BME) were 
all purchased from Fisher Scientific (Pittsburg, PA). Glycine and Tris-HCl were 
purchased from VWR International (West Chester, PA). Mini-Protean 3 electrophoresis 
system, preformed combs, glass plates and Mini Trans-Blot were purchased from BioRad 
Laboratories (Hercules, CA). Protran nitrocellulose membranes and filter paper were 
purchased from Whatman (Dassel, Germany). Mix N’ Drink, non-fat dry milk, was 
purchased from SACO Foods, Inc (Middleton, WI). See Blue Plus II pre-stained protein 
size marker was purchased from Invitrogen (Carlsbad, CA). X-ray film was developed 
using AFP Imaging Mini-Medical/90 Film Developer (Elmsford, NY) and densitometry 
performed using the Quantity One software (BioRad Laboratories). Electrophoresis 
running buffer (25 mM Tris-base, 0.2 M glycine and 3.5 mM SDS), transfer buffer (25 
mM Tris-base, 0.2 M glycine, 20% (v/v) methanol) and Tris-buffered saline (TBS; 25 
mM Tris-HCl,
 
144 mM NaCl, pH 8) were freshly prepared every two to three months. 
Tween TBS (TBST) was prepared using TBS with 0.2% v/v Tween-20. Blocking 
solution was prepared using non-fat dry milk (5% w/v) reconstituted in TBST. AC 
Imagining System was purchased from UVP BioSpectrum (Upland, CA). 
2.8.2 Preparation of Western Blot Gels 
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SDS- polyacrylamide gel electrophoresis (PAGE) gels (8%; 0.75 mm) were 
freshly prepared using the Mini-Protean 3 electrophoresis system. The lower (separating) 
gel contained acrylamide solution, 4X Tris/SDS (1.5 M Tris-base, 14 mM SDS pH 8.8), 
APS solution and TEMED. The upper (stacking) gel contained acrylamide solution, 4X 
Tris/SDS (0.5 M Tris-base, 14 mM SDS, pH 6.8), APS solution and TEMED (TABLE 
2.7). 
Reagent Stacking Gel Separating Gel 
Water 3.05 ml 4.10 ml 
Acrylamide 0.65 ml 3.33 ml 
4XTris/SDS pH 6.8 1.25 ml (-) 
4XTris/SDS pH 8.8 (-) 2.5 ml 
APS 50 !l 100 !l 
TEMED 4.5 !l 6.5 !l 
 
Wells for protein loading were created in the upper gel using preformed combs. Gels were 
stored at 4ºC for up to one week. 
2.8.3 Methods 
Pull-down protein samples (10-20 µg) were
 
boiled for 10 min and resolved on an 
8% SDS-PAGE gel. To determine correct protein size, a prestained marker (10 µl) was 
used. Proteins were resolved on 8% SDS-PAGE gels using the Mini-Protean 3 
electrophoresis system and running buffer. Proteins were transferred to nitrocellulose 
membrane in a Mini-Trans Blot Module using electrophoresis transfer buffer. Ponceau
 
S 
solution was applied to membrane and image was captured with AC Imagining System in 
TABLE 2.7: 8% SDS-PAGE gel was prepared by layering stacking gel on top of 
separating gel in glass plates separated by 0.75mm spacers.  
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order to assess equal protein loading and transfer. Membranes were incubated with 
blocking solution for 1 hour at room temperature with rocking. Membranes were washed 
3X with TBST at room temperature for 5 minutes and incubated overnight at 4°C with 
primary antibody in blocking solution (1:1000). The membranes were
 
washed 3X with 
TBST and incubated for 2 hours with appropriate secondary horseradish
 
peroxidase-
conjugated antibody diluted 1:2500 or 1:5000 in blocking solution at room temperature 
with mild agitation. Membranes were washed 3X with TBST. Bound enzymes were 
detected with ECL solution and exposed to X-ray film. Film was processed using an AFP 
Film Developer. Densitometric quantification of Western blot
 
signal intensity was 
performed using a Quantity One densitometric analysis program and corrected for equal 
protein loading.  
2.9 IMMUNOFLUORESCENCE  
2.9.1 Materials 
Citrosolv clearing agent, Permount mounting media, 22 x 60 microscope cover 
glass, Triton X, citric acid, sodium citrate and sodium borohydrate were purchased from 
Fisher Scientific (Pittsburgh, PA). Phosphate buffered saline (PBS) was purchased from 
Meditech (Hendon, VA). Paraformaldehyde and 10% (w/v) formalin solution were 
purchased from Sigma Aldrich (St Louis, MO). 4% (w/v) paraformaldehyde solution was 
prepared by reconstituting paraformaldehyde into PBS. Prolong gold anti-fade mounting 
solution, rhodamine-phalloidin, AlexaFluro secondary antibodies and 4',6-diamidino-2-
phenylindole (DAPI) were purchased from Invitrogen (Molecular Probes; Carlsbad, CA). 
Donkey and goat serum were purchased from Zymed Laboratories (San Francisco, CA). 
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Bovine serum albumin (BSA) was purchased from Roche Applied Sciences (Chicago, IL). 
ICC blocking solution (0.2% (v/v) serum and 0.1% (w/v) BSA) and IHC blocking 
solution (5% (v/v) normal goat or donkey serum, 0.3% (w/v)BSA and 0.1% (w/v) Triton 
X) were prepared in PBS. Antibodies to NMM II-A, II-B were purchased from Covance 
(Princeton, New Jersey) and NMM II-C was provided by Dr. Robert Adelstein 
(NIH/NHLBI). All NMM II antibodies were rabbit-anti-rat. Anti-human smooth muscle 
!-actin (!SMA) antibody was purchased from Dako Corporation (Glostrup, Denmark). 
Anti-glial acidic fibrillary protein (GFAP) antibodies were purchased from Santa Cruz 
(Santa Cruz, CA) and Abgent (San Diego, CA). Immunofluorescence was visualized with 
an Olympus IX71 fluorescence microscope and Fluoview FV500 version 4.3 image 
processing software (Olympus USA). 
2.9.2 Cell Preparation 
Hepatic stellate cells (HSCs) and Rat-1 fibroblasts were cultured on chamber 
slides for indicated number of days. Prior to immunocytochemistry, cells were washed 
3X with PBS (to remove non-adherent cells) and fixed in 4% (w/v) paraformaldehyde 
solution for 30 minutes at -20oC. Cells were washed with PBS 3X (10 minutes each) and 
stored at -80oC overnight. 
2.9.3 Immunohistochemistry 
Tissues were prepared as previously described (Section 2.3.3). Slides were 
incubated at 65
o
C for 1 hour, de-paraffinized with Citrosolv and rehydrated using 
descending ethanol gradient (100%, 90%, 80%, 70%, and 60%) for 10 minutes each with 
a final wash in deionized water. Cross-linked proteins were exposed using heat-induced 
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epitope retrieval and proteolytic enzyme digestion. The slides were incubated with citrate 
buffer (10 mM: 0.1 M citric acid, 0.1 M sodium citrate) in food steamer for 30 minutes 
then cooled to room temperature for 20 minutes. The slides were washed in deionized 
water and incubated on ice with sodium borohydrate (10 mg/ml in PBS) 3X for 15 
minutes. The slides were then washed and incubated with IHC blocking solution for 1 
hour at room temperature. The slides were washed and incubated overnight at 4
o
C
 
using 
rabbit polyclonal NMM II-A, II-B or II-C. GFAP and !SMA primary antibodies were 
used to detect quiescent and activated HSCs, respectively. Duplicate slides were 
incubated with PBS only and served as negative controls. The slides were washed 3X and 
incubated at room temperature for 1 hour with the appropriate fluorescent secondary 
antibodies: AlexaFluro 488 anti-rabbit and AlexaFluro 594 anti-mouse. After three 
washes, the slides were incubated with DAPI for 5 minutes, washed again (3X; 5 minutes 
each), mounted with ProLong Gold anti-fade reagent, affixed with cover glass and stored 
at 4°C. Florescent staining was visualized using the Olympus IX71. Lung tissue served as 
positive controls for anti-NMM II isoform detection. 
2.9.4 Immunocytochemistry 
Slides were thawed, washed with PBS and incubated with ICC blocking solution 
for 1 hour at room temperature. Slides were incubated overnight at 4
o
C
 
using rabbit 
polyclonal NMM II-A, II-B and II-C. Duplicate slides were incubated with PBS only and 
served as negative controls. The secondary antibody was AlexaFluro 488 goat anti-rabbit. 
The slides were then incubated for 15 minutes with rhodamine-phalloidin for F-actin 
detection, washed and incubated with DAPI for 5 minutes (2.5 µg/ml).  The slides were 
washed and mounted using ProLong Gold antifade reagent. Fluorescent staining was 
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visualized using the Olympus IX71.  Rat-1 fibroblasts served as positive controls for anti-
NMM II isoform detection. 
2.10 MATRIX STIFFNESS ASSAY 
2.10.1 Materials 
 Glass plates were purchased from BioRad Laboratories (Hercules, CA). 
Acrylamide, bis-acrylamide and ammonium persulfate (APS) purchased from Fisher 
Scientific (Pittsburg, PA) were reconstituted in deionized water. Molecular grade 
dimethyl sulphoxide (DMSO) was also purchased from Fisher Scientific. HEPES (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid) solution (1 M) and phosphate buffered 
saline (PBS) was purchased from Meditech (Hendon, VA). TEMED (N,N,N',N'-
Tetramethylethylenediamine) was purchased from EMD Chemicals Inc (Gibbstown, NJ). 
N-Sulfosuccinimidyl-6-(4'-azido-2'-nitrophenylamino) hexanoate (sulfo-SANPAH) 
purchased from Pierce Biotechnology (Rockford, IL) was reconstituted in DMSO (100 
µg/µl). Working sulfo-SANPAH solution (0.5mM) was prepared by diluting 30 µl stock, 
600 µl HEPES (50mM) and 11.34 ml deionized water. Rat tail type I collagen prepared 
in 0.02N Acetic Acid (3.65-4.5 mg/ml) was purchased from BD Biosciences (Bedford, 
MA). Gel punch ($” diameter stainless steel) was purchased from McMaster-Carr 
(Robbinsville, NJ). Syringe filters (0.45. µM) were purchased from Corning Inc (Corning, 
NY). 
2.10.2 Preparation of Polyacrylamide Substrates  
Collagen-coated polyacrylamide gels were prepared as previously described with 
minor modifications [203]. Glass plates, 0.75mm spacers, forceps and gel punch were 
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washed, rinsed with deionized water and allowed to air dry on a rack in laminar flow 
hood for 20 minutes. Once dried, materials were sterilized by UV illumination for 30 
minutes. Gels were prepared with 10% (w/v) acrylamide, 0.03 or 0.26% (w/v) bis-
acrylamide, 1% (w/v) 1M HEPES, APS, TEMED and syringe filtered. The mixture was 
poured between glass plates separated by 0.75mm spacers. Solutions were polymerized 
for 30 minutes, and gel discs were manually punched from the polymerized material 
using gel punch and placed into 24-well tissue culture plates. Sulfo-SANPAH solution 
(0.5 mM) was added to each well and photoactivated for 10 minutes with UV 
illumination (2X). The gel surface was rinsed with 50 mM HEPES 3X to remove excess 
reagent. Acrylamide gels were coated with collagen (0.2 mg/ml solution) overnight at 
4
o
C. Gels were washed with 50 mM HEPES (1X) and PBS (3X).  
2.10.3 Methods  
Primary hepatic stellate cells (3 x 106 cells/p60) were culture-activated to 
confluency for 4 days, trypsinized and seeded onto freshly prepared polyacrylamide gels 
of varying degrees of matrix stiffness (4.6 and 21.6 kPa, reported by Pelham et .al.). After 
24 hours of altered matrix stiffness exposure, cells were lysed with TRizol, RNA 
extracted and converted to cDNA as described (Section 2.5). Alterations in mRNA 
expression of NMM II isoforms were detected using RealTime PCR as described (Section 
2.6). 
2.11 siRNA-MEDIATED INHIBTION  
Multiple transfection strategies were used to down-regulate glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) and nonmuscle myosin II (NMM II) expression in 
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the LX-2 cell line and primary hepatic stellate cells (HSCs). Transfectam and Tfx-20/50 
reagents were unsuccessful in the down-regulation of GAPDH. Lipofectamine Reagent 
successfully transfected GAPDH and NMM II siRNA into primary HSCs. 
2.11.1 Materials 
GAPDH, NMM II and scramble siRNA were purchased from Ambion/Applied 
Biosystems (Austin, TX) and reconstituted with nuclease free water (TABLE 2.8). 
Trypsin-ethylenediaminetetraacetic acid (trypsin-EDTA; 0.25% (w/v)) and OptiMEM I 
Reduced Serum were purchased from Invitrogen (Gibco; Carlsbad, CA). Sodium chloride 
(NaCl) purchased from Fisher Scientific (Pittsburg, PA) was freshly prepared (150 mM 
solution) using syringe filters (0.45 µM) purchased from Corning Inc (Corning, NY). 
Gene Sense Anti-Sense Duplex # 
NMM II-A  GUGUGGUCAUUAAUCCUUAtt  UAAGGAUUAAUGACCACACag s130643 
 (Myh9) CACCUUACUCCAUUCCGAAtt UUCGGAAUGGAGUUAGGUGtg s228824* 
NMM II-B GGGAUGAAGUGAUCAAGCAtt UGCUUGAUCACUUCAUCCCgg s135203* 
 (Myh10) CAACUAUGCAUCAACUACAtt UGUAGUUGAUGCAUAGUUGtt s135204 
NMM II-C GCAUGCUUCAGGAUCGUGAtt UCACGAUCCUGAAGCAUGCtg s158958 
 (Myh14) GGAAGAUCGUGAACGGUAtt UACCCGUUCACGAUCUUCCac s158959 
 
2.11.4 Methods 
Freshly isolated HSCs were seeded at 2 x 10
6
 cells on p60 tissue culture dishes, 
incubated with DMEM supplemented with 10% (v/v) FBS and subsequently transfected 
on day 3 of culture-activation with siRNAs for NMM II isoforms (II-A, II-B and II-C) 
and GAPDH using Lipofectamine reagent. Briefly, in a 5 ml polystyrene tube (solution 
A), increasing amounts of NMM II isoforms (final concentration 10-100 nM; 25 nM 
increments) and 100 nM GAPDH and scramble siRNA were incubated with 600 µl 
TABLE 2.8: Multiple siRNA duplexes were chemically synthesized and tested in 
transfection reactions. *Indicates successful down-regulation. 
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OptiMEM and vortexed.  In a separate 5 ml tube (solution B), 10-20 µl Lipofectamine 
reagent was incubated with 600 µl OptiMEM and vortexed. Solutions A and B were 
immediately combined, vortexed and incubated for 30 minutes at room temperature. 
Cells were washed 3X with OptiMEM and incubated with 1.5 ml OptiMEM. The siRNA 
mixtures (1 ml) were then added to tissue culture dishes for 8 hours. At the end of the 
transfection incubation period, 2.5 ml of fresh media was added to the wells and 
incubated for 48 hours prior to analysis of mRNA and protein expression, contraction, 
migration and proliferation.   
2.12 FUNCTIONAL STUDIES  
2.12.1 Materials 
Endothelin-1 (ET-1), which was purchased from American Peptide (Sunnyvale, 
CA) was reconstituted in sterile deionized water. A bright line counting chamber 
hemocytometer was purchased from Hausser Scientific (Horsham, PA). 5415R 
Centrifuge was purchased from Eppendorf (Olympus USA). Trypan blue solution was 
purchased from Invitrogen (Carlsbad, CA). IX71 fluorescence microscope and Fluoview 
FV500 version 4.3 image processing software were purchased from Olympus (Olympus 
USA). 
2.12.1 Methods 
Freshly isolated HSCs were seeded at 2 x 10
6
 cells on p60 tissue culture dishes, 
incubated with DMEM supplemented with 10% FBS and subsequently transfected with 
siRNA on day 3 of culture-activation (Section 2.12.4). 
For contraction assay, collagen lattices were prepared as previously described 
(Section 2.4.2). Day 4 culture-activated/transfected HSCs were trypsinized and seeded 
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onto the congealed collagen lattice and allowed to recover overnight. Collagen discs were 
dislodged from wells with a 10 µl pipette tip. Transfected cells were treated with 
experimentally determined ET-1 concentration (1 nM; Section 2.4.5). Images were 
captured with UVP BioSpectrum AC Imagining System (Upland, CA) at indicated time 
points and the PTI ImageMaster program was used to measure changes in collagen 
diameter over time. U 
For migration assay, a sterile pipette tip was dragged through the cell sheet, 
creating a cleared zone 48 hours after transfection. Images were immediately taken of the 
scrape in four locations per dish using the Olympus IX71 microscope. 24 hours later, 
images were taken in the exact same locations. To assess the number of migrating cells, 
the PTI ImageMaster program was used to measure changes in the distance traveled into 
the ‘damaged area’ (cleared zone) after 24 hours. 
For proliferation assay, cells were trypsinized 48 hours after transfection, 
centrifuged at 500 g for 5 minutes to pellet, resuspended in media and counted on a 
hemocytometer. Trypan blue exclusion analyses were performed to determine viability. 
2.13 ASSURANCES 
All animal procedures
 
were performed under the guidelines set by the Institutional 
Animal Care and Use Committee (IACUC) at University of
 
North Carolina at Charlotte 
and
 
are in accordance with those set by the National Institutes
 
of Health.  
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FIGURE 2.1: Schematic Drawing of Centrifuged HSC Layers (Protocol A). Freshly 
isolated rat HSCs separate into two distinct buffy coat layers (yellow) in Larcoll gradient.  
 
 
 
 
 
 
HSC Layer
 
 
FIGURE 2.2: Schematic Drawing of Centrifuged HSC Layer (Protocol B and C). Freshly 
isolated rat HSCs separate into one distinct buffy coat layer in Histodenz and OptiPrep 
gradient.  
 
CHAPTER 3: IDENTIFICATION AND INHIBITION OF NONMUSCLE II MYOSIN 
ISOFORMS IN THE HEPATIC STELLATE CELL 
 
 
3.1 INTRODUCTION 
The hepatic stellate cell (HSC) is a nonparenchymal cell type located in the 
perisinusodial space of Disse between the hepatocytes and endothelial cells and 
comprises 15% of the hepatic cell population [32]. In the normal quiescent state, HSCs 
project long cytoplasmic processes through the space of Disse and reach between 
hepatocytes and sinusoidal endothelial cells (SECs) wrapping around neighboring 
sinusoids [39]. HSCs function to store vitamin A, produce collagen for extracellular 
matrix remodeling and regulate hepatic microcirculation by modulating sinusoidal 
diameter [15, 204-206]. In diseased liver states, such as steatohepatitis, fibrosis, cirrhosis, 
or hepatocellular carcinoma, damaging stimuli phenotypically transdifferentiate the 
quiescent HSCs to activated myofibroblast-like cells [43]. Additionally, activated HSCs 
proliferate vigorously, loses vitamin A droplets, increase the expression of smooth 
muscle !-actin (!SMA) and disrupt liver microcirculation by hypercontracting and 
impeding blood flow [43, 44]. Increased secretion of type I collagen changes the 
surrounding matrix, which contributes to sinusoidal constriction and perpetuates HSC 
activation leading to the clinical manifestation of fibrosis. 
In the normal liver autoregulation of microcirculation is delicately balanced by 
vasomodulators, such as endothelin-1 (ET-1) and nitric oxide [32, 114]. ET-1 is a potent 
vasoconstrictor synthesized by endothelial cells and several studies have shown that ET-1 
 
levels are elevated in patients with cirrhotic livers [115, 116, 123]. In response to 
injury, SECs release excessive ET-1, which binds ETA receptors on the HSC and 
stimulates, through calcium-dependent and -independent mechanisms, contractile force 
generation [125, 127]. Portal hypertension results from occlusion and compression of the 
sinusoidal vascular tone, which is directly mediated by increased myosin II activity in the 
activated HSC. 
Myosins are a super-family of molecular proteins that bind actin to generate force 
using ATP hydrolysis. Specifically, myosin II is responsible for the generation of 
contractile forces in cells [151]. Myosin II was first identified and characterized in 
skeletal muscles; however, related classes of myosin II have been identified in smooth, 
cardiac and nonmuscle cells [149]. The hexameric molecular motor consists of two 
identical heavy chains (MHC) and two pairs of light chains (MLC) [151]. The individual 
MHCs (head regions) consist of a catalytic motor domain, a neck region and a coil-coil 
tail region [151]. The MHC contains a nucleotide-binding region and attaches to the actin 
filament [153]. The tail region forms antiparallel complexes, which polymerize hundreds 
of myosin molecules in thick filaments of skeletal muscle cells, or as few as 28 myosins 
in nonmuscle cells [154]. A contractile force is generated to facilitate contraction, 
migration and proliferation within the cell when the ensemble of motors interact with the 
actin filaments [207]. 
Upon ET-1 binding to its receptor in smooth muscle cells, increases in 
intracellular levels of calcium are generated by cyclic adenosine 3’, 5’-monophosphate-
induced mechanism. Activation of phospholipase C-" leads to cleavage of 
phosphatodyinositol 4,5-biophosphate and the release of 1,4,5-triphosphate [122]. Influx 
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of calcium activates calmodulin-dependent MLC kinase (MLCK), which results in 
increased phosphorylation of MLC [130, 131]. Much like smooth muscle cells, HSCs 
have also been shown to signal through calcium-dependent mechanisms. Chemically 
blocking ET-1-induced activation of MLCK, with the pharmacological inhibitor ML-7, 
decreases MLC phosphorylation in HSCs and thus indicates that contraction is calcium-
dependent [127, 136]. However, it has also been shown that HSC contraction favors a 
calcium-independent pathway, specifically the Rho/ Rho kinase pathway [136, 198].  
By using a selective inhibitor for Rho kinase (ROCK; Y-27632), studies have 
shown that HSC contraction is predominately mediated through the RhoA pathway [134]. 
In this pathway, increased phosphorylation of myosin II occurs through inhibition of the 
myosin phosphatase as well as through direct phosphorylation of MLC by ROCK leading 
to stress fiber formation and cellular contraction. Treatment with a ROCK inhibitor not 
only impedes ET-1 induced contraction of activated HSCs, but it also inhibits the 
progression of hepatic fibrosis as evident by decreased collagen accumulation and 
perpetual HSC activation. However, this fibrogenic response has also been shown to be 
mediated through the angiotensin II signaling pathway [134, 135]. Therefore, 
distinguishing between ROCK-induced contractile properties and other cellular responses 
mediated through ROCK requires a more selective and direct inhibition of HSC 
contraction. 
Blebbistatin is a potent, selective and reversible pharmacological inhibitor of 
myosin II ATPase activity; however, tissue specificity of the drug is not well understood. 
Blebbistatin preferentially
 
binds to the ATPase intermediate of the myosin II molecule, 
which inhibits phosphate release and thus actin dissociation and activated ATPase 
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activity [134, 170]. While studies have shown blebbistatin is an inhibitor of skeletal and 
nonmuscle myosin II activity, with minimal effects on smooth muscle myosin II, others 
have suggested that blebbistatin is specific to nonmuscle myosin II (NMM II) [164, 169-
171]. Direct chemical inhibition of myosin II activity, rather than blocking upstream 
signaling events, is important in determining the functional role of the motor protein 
within the cell.  
Although the structural cores of the myosin II classes are homologous, the minor 
amino acid alterations in the heavy and light chains alter kinetic and biochemical 
properties of the motor [172]. Specifically in nonmuscle cells, three isoforms of myosin 
II encoded by different genes have been identified in multiple tissues, NMM II-A, II-B 
and II-C [186]. The distinct enzymatic properties of each isoform allow for fine tuning of 
mechanical properties and are important in modulating the functional role of each 
isoform in the cell [190]. It has previously been shown that NMM II plays a role in many 
highly dynamic and transient cellular processes including cytokinesis, cell motility and 
cell polarity in many eukaryotic cells [149].  
The structure and kinetics of NMM II isoforms may be useful in understanding 
the contractile properties of the HSC. HSCs express both myosin II and actin proteins; 
however, the particular class of myosin II has not been identified in HSCs. Thus, since 
HSCs are nonmuscle cells, we chose to investigate NMM II expression and localization 
of the three different NMM II isoforms in quiescent and activated HSCs.  
One of the key phenotypic responses of the HSC that occurs during liver damage 
is changes in the extracellular matrix (ECM) of the liver. ECM remodeling leads to 
disruption of the liver architecture and thus accelerates HSC activation. This perpetual 
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activation of the HSC has been attributed to the ECM components such as type I collagen 
that increases matrix rigidity. Therefore, since HSCs can respond to changes in ECM, 
studies were performed to alter matrix stiffness to investigate changes in ECM as a 
possible mechanism for NMM II isoform regulation. Finally, this study selectively 
inhibited myosin II activity in the HSCs using blebbistatin, which allows us to closely 
scrutinize the specific role of myosin II in HSC contraction.  
3.2 RESULTS 
3.2.1 Blebbistatin inhibits basal- and vasoconstrictor-induced contraction of HSCs 
HSC transdifferentiation is a key element in the development of portal 
hypertension. Understanding specific molecular components that are upregulated in this 
process requires identification of myosin II classes in quiescent, and early- and late- 
activated HSCs. As seen in fibrotic conditions, increased collagen type I deposition 
increases the matrix rigidity of the liver; therefore culturing freshly isolated HSCs on 
plastic tissue culture dishes mimics this in vivo environment. Culture-activated HSCs lose 
retinol esters, spread out and increase expression of !SMA; all of which are 
characteristic of activated HSCs (FIGURE 3.1). Using this in vitro model provides a 
method to measure the daily genetic and morphological changes in the process of HSC 
transdifferentiation. 
To validate our in vitro HSC collagen contraction assay, we showed that culture-
activated HSCs were contractile and responsive to the vasoconstrictor, ET-1 (Section 
2.4.2). Collagen lattices prepared using an 8:1:1 rat tail type I collagen: 0.02 N Acetic 
Acid (3.65-4.5 mg/ml): 0.2 M HEPES: 10X DMEM solution. Day 4 culture-activated 
HSCs were trypsinized and seeded onto collagen lattices. Cells were serum starved for 24 
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hours and subsequently treated with increasing doses of ET-1 to determine optimal 
vasoconstriction concentrations (0; 0.1 pM - 100 nM; logarithmic increments). HSCs 
have previously been shown to be the most responsive to ET-1 on day 5 and the proteins 
(!SMA, myosin II and ETA and ETB receptors) responsible for contraction are not 
expressed in abundance until day 5, thus we chose this day of culture-activation [208]. In 
addition, other investigators routinely use day 5 for HSC contraction studies [32, 209]. 
The optimal volume and concentration of type I collagen in the collagen lattices and cell 
number was determined to be 300µl of 3.65 mg/ml collagen solution and 300,000 cells/ 
1.88 cm2 well. The optimal concentration of ET-1 after 24 hours was determined to be 
1nM, as this concentration significantly decreased the collagen lattice diameter to 28.5% 
of the original collagen diameter, while higher doses of ET-1 did not result in further 
contraction (FIGURE 3.2).  
Myosin II activity regulates cell morphology and HSC contraction; however, this 
hypothesis had not been tested with a selective inhibitor of myosin II activity, all 
previous studies manipulated upstream effectors of myosin II activity. Therefore, we 
tested the effects blebbistatin had on HSC morphology and contraction. Day 4 culture-
activated HSCs were seeded on collagen lattices and serum starved overnight (FIGURE 
3.3). The wells were then pretreated with blebbistatin for 30 minutes and treated with the 
optimal ET-1 dose (1 nM). Consistent with previous findings, day 5 HSCs were 
contractile and exhibited a star-like shape when seeded onto a collagen lattice (FIGURE 
3.3A). ET-1 treatment caused HSC hyperconstriction and changed the phenotype into a 
stretched polygon morphology reaching across the collagen lattice (FIGURE 3.3B). As 
expected, pre-treatment with blebbistatin (50 µM) inhibited ET-1 induced 
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hyperconstriction of the cell morphology (FIGURE 3.3C), while vehicle treatment pre-
treatment permitted ET-1 induced hyperconstriction of the HSCs (FIGURE 3.3D).  
In addition, we also tested the effects of blebbistatin on basal- and ET-1-induced 
HSC contraction of collagen lattices. HSCs were pretreated with increasing doses of 
blebbistatin (0-25 µM; 5 µM increments) for 30 minutes followed by ET-1 (1 nM) 
treatment. As the HSCs contracted, the collagen lattice decreased in circumference. The 
cells pretreated with higher doses of blebbistatin (15-25 µM), abolished basal- and ET-1 
induced contraction, while lower doses of blebbistatin (5 and 10 µM) significantly 
inhibited ET-1 induced contraction (FIGURE 3.4; light grey bars). 
Additionally, we demonstrated that 5µM blebbistatin treatment decreased the rate 
of HSC contraction 36% as compared to the vehicle (vehicle pre-treatment contraction 
rate= 0.0577 cm2/hour; blebbistatin pre-treatment contraction rate= 0.0208 cm2/hour) 
after 24 hours (FIGURE 3.5). Overall, by using the selective pharmacological agent, 
blebbistatin, our results demonstrated that myosin II activity maintained HSC cellular 
morphology, completely abrogated its contractile properties and modulated the rate of 
contraction. 
3.2.2 NMM II isoform expression in HSCs 
Our initial study with blebbistatin confirmed that myosin II is present in the HSC 
and directly responsible for contraction; however there are multiple classes of myosin II: 
the sarcomeric myosins from skeletal, cardiac muscle and smooth muscle cells, 
nonmuscle myosins, and the myosin II from lower eukaryotic species and fungi [149]. 
Since HSCs are nonmuscle cells, we chose to focus on the nonmuscle myosins but 
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keeping in mind that the identification of other myosin II family members, such as 
smooth muscle myosins, may also be important and may warrant further investigation.  
To demonstrate that specific NMM II isoforms are expressed by HSCs, freshly 
isolated cells (quiescent), day 1 and day 14 culture-activated HSCs were measured by 
reverse transcriptase PCR (RT-PCR) and RealTime PCR to visualize and quantify 
mRNA expression, respectively (Section 2.6.2 and 2.6.3). Primers were designed using 
OLIGO 6 program and validated using lung control as a positive control (FIGURE 3.6). 
As determined by RT-PCR, mRNA expression of all three isoforms was detected and 
visualized on an agarose gel (FIGURE 3.7).  HSCs were freshly isolated (quiescent) from 
rat livers as described in Section 2.2.2 and culture-activated HSCs (day 1 and 14) were 
harvested from tissue culture dishes as described in Section 2.1.4. RNA was generated 
from HSCs as previously described in Section 2.5.2 and reverse transcribed to cDNA 
with SuperScript III Reverse Transcription System. The housekeeping gene, GAPDH, 
was initially used as a method of myosin II isoform normalization; however, our studies 
indicated that this method was not appropriate due to variations in expression of this gene 
over days in culture-activation (FIGURE 3.8). Other standard housekeeping genes, 
including "-actin and HPRT were also tested for normalization of NMM II isoform 
expression. These genes were also not suitable for mRNA normalization since there were 
wide variations in mRNA expression based on total cDNA content (FIGURE). Therefore, 
total cDNA, as determined by NanoDrop concentration measurements, was used for 
normalization to quantitate changes in gene expression. 
Using RT-PCR, in vitro data revealed mRNA expression of all three isoforms in 
quiescent and culture-activated HSCs (day 1 and 14). Strong mRNA expression of NMM 
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II-A was detected at 28 cycles; while expression of NMM II-B and II-C was detected at 
34 and 42 cycles, respectively (FIGURE 3.7A). Using RealTime PCR to quantify mRNA 
expression of NMM II isoforms normalized to total cDNA concentrations, NMM II-A 
and II-B were significantly increased by culture-activation, whereas expression of NMM 
II-C was variable (FIGURE 3.7B). Interestingly, mRNA expression of NMM II-B 
increased 2.8-fold over culture-activation, whereas NMM II-A expression only increased 
1.4-fold suggesting that NMM II-B maybe play and important role in the later stages of 
HSC transdifferentiation. 
To determine if mRNA expression correlated with protein expression, whole cell 
extracts were harvested from HSCs and subjected to precipitation by F-actin selection as 
previously described in Section 2.7.2. Using Western blots to analyze protein expression 
of NMM II isoforms (Section 2.8.3), our studies indicated no detectable expression of all 
three isoforms in quiescent cells, which was unexpected since mRNA expression was 
present (FIGURE 3.9; NMM II isoform 1:1000 antibody dilution). To confirm these 
results, the concentration of quiescent samples was doubled and reanalyzed; although 
Ponceau S staining verified total protein loading of quiescent samples increased twofold,  
expression of all three isoforms still was undetected in quiescent samples. All three 
isoforms were present after initiation of HSC activation (day 1), but showed relatively 
weak expression as compared to the protein expression in fully activated cells (day 14). 
As shown in FIGURE 3.9, there was a strong increase in protein amounts for all three 
isoforms at fully activated HSCs (day 14), NMM II-A and II-B showing significant 
increases. Since NMM II-A and II-B have been shown to play individual roles in 
migration and contraction, it is possible that they perform different roles in the activated 
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HSC as well, providing separate targets for different cellular functions. Although the 
function of NMM II-C has not been identified, it too increased with culture-activation, 
suggesting yet another contributor to cellular function. 
NMM II-A and II-B are distributed along stress fibers, in a linear or interspersed 
fashion within lamellipodia and co-localize around the nucleus [195]. The NMM II-A 
isoform preferentially co-localizes with actin filaments in the leading edge of cells, while 
II-B co-localizes in the trailing edge [195]. In order to visualize the protein expression of 
each isoform, culture-activated HSCs were sparsely seeded onto plastic chamber slides 
and immunocytochemistry was performed ( Section 2.9.4). As determined by 
immunofluorescence, protein expression of three isoforms was detected in culture-
activated cells (FIGURE 3.10; NMM II 1:500 antibody dilution). Initial activation of 
HSCs at day 1 produced weak expression, whereas full activation at day 14 showed 
strong but variable expression. At day 14, expression of NMM II-A and II-B was co-
localized to actin stress fibers, while expression of NMM II-C was dispersed.  
In order to determine if NMM II expression is upregulated in liver fibrosis, bile duct 
ligation (BDL) induced liver injury was performed as described in Section 2.3.2. Fibrosis 
induced by BDL typically generates lesions surrounding the bile duct epithelium and 
gives rise to uncontrolled proliferating cholangiocytes, which results in hepatic injury 
[24]. HSCs respond to stimulation and become activated. Sham operations were 
performed in the same manner, except without BDL. Our results, as determined by Sirus 
red staining (performed by Carolinas Medical Center Department of Surgery) and 
hematoxylin and eosin (H&E; Section 2.3.4) staining, are consistent with previous 
findings of liver injury induced by BDL (FIGURE 3.11). While Sirus red staining 
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indicated increased levels of collagen deposition in fibrotic liver tissue, H&E staining 
confirmed uncontrolled proliferation of the biliary epithelium. 
As seen in culture-activation, mRNA expression levels of !SMA in HSCs are 
increased 2,000-fold (FIGURE 3.12A), thus this protein is typically used as a classic 
marker of liver fibrosis. We have also shown that glial fibrillary acidic protein (GFAP) 
mRNA expression is upregulated in quiescent HSCs; therefore, we expected that protein 
expression should be increased in normal liver tissue (FIGURE 3.12B). We used 
immunofluorescence to detect these protein markers in normal and injured liver tissues 
(FIGURE 3.12C). Expression of !SMA was evident in the smooth muscle cells 
surrounding the central vein exclusively, while expression in the injured tissue was 
intercalated between hepatocytes, where HSCs normally reside. Unexpectedly, 
expression of GFAP was undetected by immunofluorescence in both normal and injured 
liver tissue (data not shown). We used multiple antibodies from different companies and 
various tissues; however, we were unable to use this protein marker for fluorescent 
quiescent HSC detection. 
  In order to determine if NMM II expression was upregulated in liver fibrosis, we 
used fluorescent immunohistochemistry to co-localize isoform expression with !SMA 
positive cells (activated HSCs) in injured liver tissue (FIGURE 3.13). Only NMM II-A 
and II-B protein expression was minimally detected in normal liver tissue, while NMM 
II-B was the only isoform found to co-localize with activated HSCs in injured liver 
tissue.  
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3.2.4 Substrate stiffness modulates NMM II isoform expression of HSCs 
 Previous studies have shown that HSC transdifferentiation is dependent on matrix 
stiffness (Wells). In cirrhotic patients, liver stiffness measurements range from 12.5 to 
75.5 kPa [76]; therefore we generated polyacrylamide substrates coated with a thin layer 
of type I collagen to mimic this in vivo environment. To test the effects of changes in 
mechanical rigidity on NMM II isoform expression, we seeded day 5 culture-activated 
HSCs on ‘normal’ and ‘fibrotic’ substrates (4.6 and 21.6 kPa) and allowed the cells to 
incubate overnight. As assessed morphologically, culture-activated HSCs seeded onto 
‘normal’ substrate reverted to their quiescent phenotype, while cells seeded onto 
‘fibrotic’ substrate maintained myofibroblastic projections characteristic of the activated 
phenotype (FIGURE 3.14A). Using RT-PCR analysis, we demonstrated that expression 
of both NMM II-A and II-B were downregulated in cells plated on softer substrate 
supports (FIGURE 3.14B). While expression of NMM II-A was decreased moderately, 
NMM II-B expression was significantly decreased 21%, indicating a regulatory role for 
matrix stiffness on isoform expression (FIGURE 3.14C).  
3.3 DISCUSSION 
HSCs play several important roles in facilitating the hepatic immune response. 
Quiescent HSCs in a healthy liver maintain normal hepatic microcirculation by wrapping 
around liver sinusoids and contract and dilate in response to local vasoactive modulators, 
notably ET-1 and nitric oxide. However, during acute injury, HSCs hyperconstrict blood 
vessels, allowing for architectural stabilization and reduced toxin influx. HSCs also 
undergo a transdifferentiation process from the quiescent state to an activated 
myofibroblast-like cell. The activated cells divide and migrate to the site of injury where 
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they secrete fibrillar collagen. If the injury persists , the HSC’s wound healing responses 
never resolves and excessive collagen accumulates and blood vessels constriction is 
sustained. By modulating collagen biosynthesis, it has been suggested that fibrosis is 
partially reversible [6]. However, complete resolution of excessive collagen deposition in 
a cirrhotic liver with restoration of normal hepatic microcirculation may not be possible. 
Current treatment for fibrosis and cirrhosis focuses on portal hypertension and its 
complications; however, these treatments do not have an effect on the pathophysiological 
mechanisms that lead to portal hypertension. Thus, effective vasodilating drugs directed 
towards HSC contractility may be beneficial. 
In order to establish an effective treatment regime directed at HSC 
hypercontractility, migration and proliferation, an in depth understanding of the 
intracellular components and pathways is necessary; however, no studies to date have 
identified these specific proteins and pathways.  Prolonged exposure to a fibrogenic insult 
has been shown to increase myosin II protein expression in HSCs, which is necessary for 
contractility [209]. By inhibiting ROCK, an upstream effector of myosin II activity, HSC 
contraction is prevented; however, blocking the upstream Rho pathway also interferes 
with a wide range of cellular functions including contraction, migration, apoptosis and 
proliferation by targeting LIM kinase, Akt and the ERK pathways, respectively, which all 
phosphorylate MLC [167]. No studies have examined direct inhibition of myosin II on 
contraction. In this study we used a myosin II inhibitor, blebbistatin, which is a cell-
permeable specific pharmacological inhibitor of myosin II ATPase activity, to block HSC 
contraction. Blebbistatin has previously been used to inhibit protrusion-mediated lamella 
formation and chemotactic migration of HSCs [45]. While the IC50 values of blebbistatin 
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range from 0.5 to 5 µM for myosin II isoforms, smooth muscle myosin II is weakly 
inhibited with an IC50 value of 80 µM. Our studies demonstrated that blebbistatin inhibits 
ET-1-induced contraction with an IC50 value of 5 µM, which is consistent with previous 
findings [210]. Blocking myosin II activity subsequently inhibited both basal- and ET-1- 
induced contraction of the HSCs, demonstrating for the first time that that myosin II 
plays a direct role in HSC contraction. 
Tissue and isoform specificity of blebbistatin is not well understood. While some 
studies describe that the pharmacological inhibitor can block skeletal muscle and NMM 
II activity with minimal effects on smooth muscle myosin II, others have shown that 
blebbistatin is specific to smooth muscle myosin II; therefore,  it is possible that smooth 
muscle and nonmuscle myosin II may contribute to HSC contraction [164, 169-171]. 
Since HSCs are nonmuscle cells, we chose to examine the expression of NMM II 
isoforms in the process of HSC transdifferentiation.  
Protein and mRNA expression of all three NMM II isoforms were detected in culture-
activated cells. Interestingly, protein expression of all isoforms was undetectable in 
quiescent cells, while mRNA expression was detected. The process of HSC 
transdifferentiation is a key element in liver fibrosis and understanding the expression of 
NMM II isoforms in early (day 1) and late (day 14) HSC culture-activation provides 
possible insights into their particular cellular functions. Since NMM II-A and II-B 
contribute to cellular migration and contraction, it is possible that these isoforms perform 
different roles in the progression of HSC transdifferentiation as well. Although the 
function of NMM II-C has not been identified, it too increases with culture-activation, 
suggesting yet another contributor to cellular functioning. 
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In order to associate isoform expression with a particular cellular function we 
determined isoform location. Using immunofluorescense, we showed that NMM, II-A 
and II-B co-localized to actin stress fibers suggesting that these molecules are 
functionally active. Strong expression of NMM II-A in the periphery of activated HSCs 
may be important in migration of HSCs, while strong NMM II-B expression in the 
cellular cortex may indicate an important role for this isoform in controlling the 
hypercontraction of the HSC during injury. Expression of NMM II-C however was not 
clearly distinguishable, indicating that isoform may be in too low of quantities to be 
detected by this technique or may possibly be an artifact of the assay.  In vivo studies 
only demonstrated upregulation of NMM II-B isoform expression in activated HSCs. 
Although this data remains inconclusive, it is possible that fluorescent technique 
employed was unable to delineate between expressions of the other isoforms in 
surrounding cells. We expect that future studies measuring the genetic inhibition of each 
NMM II isoforms will delineate the functional roles of the isoforms in culture-activated 
HSCs. These studies are described in the following chapter.  
Activated HSC increase synthesis and deposition of type I collagen accompanied 
with changes in matrix metalloproteinases and its inhibitors. This overall accumulation of 
type I collagen increases the matrix stiffness of the basement membrane. It has been 
suggested that increased matrix rigidity is associated with perpetual HSC activation [72].  
However, it is not clear if increased static pressure of hepatic sinusoids itself influences 
the functional transformation of HSCs. Early symptoms of chronic liver disease are often 
presented with clinical features attributable to portal hypertension. A recent study 
demonstrated that increased static pressure and ethanol exposure can modulate HSC 
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activation in vitro [211]. The results suggest that increased matrix stiffness accompanied 
by sinusoidal static pressure will result in the continual activation of the HSC.  Thus, we 
tested the relative contribution of matrix stiffness on isoform modulation. Our results 
indicated that mechanical properties of the liver can alter NMM II isoform expression 
providing insight to the mechanism of HSC-induced sinusoidal constriction.  
Overall these studies show that myosin II is the primary molecular motor 
responsible for HSC contraction by using the selective inhibitor of the NMM II ATPase 
intermediate of the myosin II molecule, blebbistatin. Additionally, we determined the 
expression and localization of NMM II isoforms in quiescent and activated HSCs and 
based on cellular location, our data suggest that II-A could participate in the initial force 
generation necessary for migration, while II-B may participate in sustained 
hypercontraction. Finally, we have shown that NMM II isoform expression may be 
modulated through mechanical properties, such as matrix stiffness. 
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FIGURE 3.1: Culture-activated HSCs Transdifferentiate into !-SMA Expressing 
Myofibroblasts. HSCs plated onto plastic tissue culture dishes proliferate vigorously, lose 
retinol esters and increase mRNA expression of smooth muscle a-actin. (A) On day 1 of 
culture-activation, retinol esters (white) are present in abundant quantity. By day 5 of 
culture activation, retinol esters and cytoplasmic projections (black arrows) have 
depleted. (B) Over days in culture, activated HSCs increase mRNA expression of smooth 
muscle !-actin approximately 2000-fold as measured by RealTime PCR (*p<0.05 
compared to Day 1.) 
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FIGURE 3.2: ET-1 Treatment Induces HSC Contraction of Collagen Lattices. Optimal 
ET-1 concentration was determined using increasing doses of the peptide. (A) 
Representative collagen contraction assay. (B) Quantification of ET-1-induced HSC 
collagen contraction. Day 5 culture-activated HSCs were seeded onto the lattices and 
treated with increasing doses of ET-1. Day 5 HSCs, contracted the collagen lattice 
(control or basal) and increasing doses of ET-1 amplified the contraction. Percent change 
in gel circumference peaked at 71.5% with 1nM ET-1 treatment. PCR (*p<0.05; 
#p<0.001 compared to Control.)    
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FIGURE 3.3: Blebbistatin Inhibited ET-1-Induced Changes in HSC Morphology. HSCs 
seeded onto a collagen lattice with no chemical treatment exhibit a star-like structure (A). 
HSCs treated with ET-1 (B) become hypercontractile and change their morphology to a 
stretched polygon morphology compared to untreated cells (A). When pretreated with 
vehicle, and subsequently incubated with ET-1, HSCs again exhibited a stretched 
polygon structure (C); however, blebbistatin pre-treatment, inhibited ET-1 induced 
morphological changes in HSC structure (D). 
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FIGURE 3.4: Blebbistatin Inhibited Basal and ET-1-Induced HSC Contraction. Optimal 
blebbistatin concentration was determined by inhibition of gel contraction. Day 5 culture-
activated HSCs seeded onto gels were pretreated with vehicle or blebbistatin and 
subsequently treated with 1nM ET-1 after 30 minutes. (A) Representative image of 
blebbistatin inhibition of ET-1 induced contraction. (B) Blebbistatin, a myosin II 
inhibitor, blocked HSC contraction. Pretreatment with 5mM blebbistatin diminished ET-
1 induced constriction by 54%, while 15-25mM completely abrogated ET-1 induced 
constriction. (*p<0.05 compared to the untreated sample.) 
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FIGURE 3.5: Blebbistatin Inhibited ET-1 Induced HSC Contraction Rate. HSCs seeded 
onto collagen lattices and treated with ET-1 and the vehicle, contracted maximally at 
80.8%, while blebbistatin pre-treatment inhibited ET-1-induced contraction ~50% after 
24 hours. Blebbistatin pre-treatment decreased the rate of HSC contraction 36% over 24 
hours (vehicle=0.0577cm
2
/hour; blebbistatin=0.028cm
2
/hour). 
 
 
 
 
 
 
 
 
 
FIGURE 3.6: NMM II Isoform mRNA Expression in the Lung. Lung tissue mRNA was 
used to detect NMM II expression of all three isoforms by RT-PCR. Expression of all 
three isoforms was observed at the predicted base pair. 
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FIGURE 3.7: RT and Real-Time PCR Quantification of NMM II-A, II-B and II-C 
mRNA Expression in HSCs. (A) mRNA expression of all isoforms was detected in 
quiescent and culture-activated HSCs (day 1 and 14) by RT-PCR and visualized on an 
agarose gel. Strong mRNA expression of NMM II-A was detected at 28 cycles, while 
expression of NMM II-B and II-C was detected at 34 and 42 cycles, respectively. (B) As 
normalized to total cDNA concentration, mRNA expression of all isoforms was induced 
by culture-activation. Real-Time PCR indicated that NMM II-A mRNA expression was 
higher in quiescent cells compared to II-B and II-C; however, mRNA expression of II-B 
increased dramatically (55%) over days in culture. NMM II-C expression across culture-
activation was variable. (*p<0.05; #p<0.001 as normalized to total cDNA concentration) 
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FIGURE 3.8: Housekeeping Gene mRNA Expression from Cultured HSCs. (A) mRNA 
expression of GAPDH was detected after 23 cycles by RT-PCR in quiescent and culture-
activated HSCs (day 1 and 14). (B) As normalized to total cDNA concentration, mRNA 
expression of classic housekeeping genes (G3PDH, "-actin and HPRT) fluctuated over 
days during culture- activation, thus they served as unreliable normalization markers for 
NMM II isoform expression as determined by Real-Time PCR. 
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FIGURE 3.9: Quantification of NMM II-A, II-B and II-C protein expression in HSCs. 
(A) Protein expression of all three NMM II isoforms was undetected in quiescent HSCs 
by Western blot analysis. Initial activation of HSCs at day 1 produced weak NMM II 
isoform expression, whereas full activation at day 14 showed strong but variable 
expression (M.W.=200kD). (B) Quantification of Western blot. Protein expression of 
each isoform was normalized to protein expression of positive control (Rat-1 fibroblast 
cell line; *p<0.01). 
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FIGURE 3.10: Immunocytochemistry: Protein Expression of NMM II-A, II-B and II-C in 
HSCs. Expression of all three isoforms was detected in culture-activated cells. At day 14 
of culture-activation, expression of NMM II-A and II-B was co-localized (yellow) to 
actin stress fibers (phalloidin stain-red), while expression of NMM II-C was dispersed. 
Rat-1 fibroblast cell line served as a positive control. 
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FIGURE 3.11: Bile Duct Ligation Induced Hepatic Fibrosis. BDL is a well-established 
model of hepatic fibrosis. The common bile duct is double-ligated and transected (right 
panel). Sham operation was performed in the same manner expect without BDL (left 
panel). Tissue was stained by Sirus red (top panel) and H&E (bottom panel) to assess 
liver morphology. Increased collagen deposition (red) was evident in copious amounts in 
BDL tissue (B), while sham tissue exhibited mild staining around the portal triad (A). An 
increase in cellular proliferation was evident by increased hemotoxylin staining (blue) in 
the portal tract (black arrows) of BDL tissue (D). 
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FIGURE 3.12: Classic Protein Markers of Quiescent and Activated HSCs. Culture 
activation of quiescent HSCs (A) up-regulated the expression of !SMA and (B) down-
regulated the expression of GFAP as determined by Real-Time PCR. Protein expression 
of !SMA (green) was detected in normal tissue surrounding central vein, while injured 
liver tissue showed abundant expression as determined by fluorescent 
immunohistochemistry (C).  
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FIGURE 3.13: Immunohistochemistry: Protein Expression of NMM II-A, II-B and II-C 
in Normal and Injured Liver Tissue. Normal liver tissue from a sham rat demonstrated 
the presence of NMM II-A and II-B but not II-C. Injured liver tissue from bile duct 
ligated rats also demonstrated expression of NMM II-A and II-B, as well as II-C. 
Additionally, only II-B co-localized with activated HSCs in the injured tissue. Lung 
tissue served as positive control.  
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FIGURE 3.14: NMM II Isoform Expression is Regulated by Matrix Stiffness. As seen in 
normal liver conditions (liver stiffness ~ 4.6 kPa), day 5 culture-activated HSCs maintain 
quiescent phenotype (A), while cells seeded onto ‘fibrotic’ substrates (liver stiffness ~ 
21.6 kPa) display myofibroblastic morphology (B). Cells were lysed for RT-PCR 
analysis; NMM II-B expression of cells seeded onto ‘fibrotic’ substrate was increased 
significantly (C).  
 
CHAPTER 4: GENETIC INHIBITION OF NONMUSCLE II ISOFORMS IN THE 
HEPATIC STELLATE CELL 
 
 
4.1 INTRODUCTION 
 Regulation of the liver microcirculation is a complex system where blood flow is 
under systemic and sinusoidal control. In a healthy liver, the quiescent HSC stores 
vitamin A, produces collagen for basement matrix remodeling and wraps around 
sinusoids, which regulates sinusoidal diameter, and thus blood flow, by contracting and 
dilating in response to local vasoactive modulators. In a damaged liver the HSC 
undergoes a transdifferentiation process resulting in multiple phenotypic and genotypic 
changes, which coordinate the contractile, migratory and proliferative phenotype of the 
activated HSC. Upon a fibrogenic stimulus, such as excessive alcohol intake, increased 
oxidative stress stimulates HSC activation. The activated HSC produces excessive 
collagen, loses vitamin A stores and disrupts liver microcirculation by exerting a 
sustained contractile force on the sinusoid, thus contributing to increased intrahepatic 
vascular resistance and portal hypertension. This hypercontractile phenotype of the 
activated HSC is associated with increased myosin II activity within the cell [32].  
Myosins are a large super-family of molecular proteins that play important 
cellular roles in contraction, cytokinesis, motility and trafficking. Specifically, myosin II 
is responsible for generating contractile forces [149]. Myosin II was first identified and 
characterized in skeletal muscles; however, related classes of myosin II have been 
identified in cardiac, smooth and nonmuscle cells [149].  
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  Three isoforms of NMM II (II-A, II-B and II-C) differ in the sequence analysis of 
the catalytic motor domain which allows for fine-tuning of specific cellular functions 
[190]. NMM II-B has a higher ADP affinity, thus spends the majority of its kinetic cycle 
bound to actin, while NMM II-A spends a smaller fraction of its kinetic cycle attached to 
actin [190]. The slower ADP release and long attachment time to actin make NMM II-B 
an ideal candidate for long term force maintenance, while the faster NMM II-A may be 
involved in the rapid tension generation [186]. In addition to variations in kinetic 
properties, the isoforms demonstrate varying expression levels in HSCs (FIGURES 3.7 
and 3.9). While NMM II-A mRNA expression is higher in quiescent cells compared to II-
B and II-C, expression of II-B increases 55% over days in culture, as compared to a 28% 
increase of II-A.  
Genetic mutations of NMM II-A and II-B are lethal in mice due to cardiac and 
brain defects, indicating that these isoforms are functionally necessary [212-214]. 
Additionally, the cellular localization and kinetic properties of NMM II-A and II-B 
suggest that these isoforms are involved in specific functions, such as migration and 
contraction. NMM II null cells derived from embryos have impaired migratory and 
contractile properties [215, 216]. Additionally, siRNA-mediated knock-down of NMM II 
isoforms in neurons [213], cancer cells [217, 218] and fibroblast [219] modulate 
contraction and migration. Since the activated HSC phenotype closely resembles 
fibroblast cells, using siRNA-mediated knock-down of NMM II isoforms in HSCs would 
be a suitable approach to antagonize the contractile, migratory and proliferative activated 
phenotype. Therefore, the purpose of this study was to determine if hypercontraction, 
migration and proliferation of activated HSCs are associated with modulation of specific 
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NMM II isoform expression during culture-activation and whether each isoform 
contributes to a certain cellular function.  
4.2 RESULTS 
4.2.1 Human HSC cell line, LX-2, as a model of HSC contraction 
One important limitation in studying cellular function
 
in primary HSC cultures is 
transfection efficiency. To address this difficulty, Xu
 
et al. established the human hepatic 
cell line, LX-2, which recaptures the activated phenotype of HSCs [220]. LX-2 cells 
retain
 
the typical characteristics of activated HSCs such as upregulated platelet-derived 
growth factor, transforming growth factor ("1) and fibrogenic pro-collagen (!1) 
expression, making them a suitable tool for in vitro studies of human
 
hepatic fibrosis. 
Previous studies suggest that LX-2 cells respond to fetal bovine serum-stimulated 
contraction of collagen lattices; however, direct measurements were not reported [120].  
In order to determine if human LX-2 cells retain the hypercontractile properties of 
day 5 culture-activated rat HSCs, we used a collagen contraction assay (Section 2.4) to 
test the effects of ET-1 on LX-2 cellular contraction. LX-2 cells grown to confluency 
were trypsinized and seeded onto prepared collagen lattices. Cell concentrations between 
2.5 x 105 and 5.0 x 105 cells were tested to determine optimal cell number (FIGURE 4.1). 
Cells were serum starved for 24 hours and subsequently treated with ET-1 (1nM). As 
compared to ET-1 induced contraction of HSCs, LX-2 cells did not induce collagen 
lattice contraction after 24 hours. HSCs are most responsive to ET-1 on day 5 and the 
contractile proteins, !SMA, myosin II and ETA and ETB receptors, are not expressed in 
abundance until day 5 [208]. Thus it may be possible that the LX-2 cell line, which most 
closely emulates the fully activated HSCs (day 14) phenotype may not express the 
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contractile proteins necessary to induce a change in collagen lattice diameter. Although 
transfection of small interfering RNA (siRNA) to inhibit NMM II isoform expression 
may be more efficient and clinically relevant in the human LX-2 cell line as compared to 
rat primary cell cultures, we would be unable to determine significant differences in 
cellular contraction attributed to isoform knock-down.  
4.2.2 Transient transfection of GAPDH and NMM II isoforms in primary HSCs 
To determine if we could utilize siRNA-mediated knock-down of gene expression 
in primary HSC cultures, we transiently transfected day 3 culture-activated HSCs with 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) siRNA for 48 hours. Scramble 
siRNA that has no significant homology to any know gene sequence was used as a 
negative control. Preliminary studies were carried out to determine optimal lipofectamine 
reagent volume and siRNA concentration (FIGURE 4.2). RT-PCR measurements 
indicated that HSCs incubated with 10 µl of lipofectamine and 300 nM GAPDH siRNA 
optimally down-regulated the expression of GAPDH mRNA expression (FIGURE 4.3).  
To demonstrate that we can inhibit a specific NMM II isoform in primary rat 
cultures, HSCs were transiently transfected with increasing doses of NMM II isoform 
siRNAs. Six permutations of these genes were transfected into the cells to determine if 
more than one gene can be down-regulated at the same time (II-A, II-B and II-C only; II-
A and II-B, II-A and II-C, II-B and II-C). Preliminary studies were carried out to identify 
optimal siRNA duplexes (TABLE 2.8) and concentration for each isoform. 
To determine optimal duplexes and concentrations for the NMM II-A isoform, 
day 3 culture-activated HSCs were incubated with increasing doses (50-100 nM) of 
NMM II-A siRNA duplex #1 or #2 for 48 hours (Section 2.12.2). As determined by RT-
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PCR, HSCs transfected with siRNA specific to NMM II-A duplex # 2 resulted in a 53% 
inhibition of mRNA expression using 100nM concentration compared to the cells 
transfected with a scramble siRNA (FIGURE 4.4A).  RealTime PCR measurements also 
confirmed these results, as NMM II-A siRNA duplex #2 resulted in a 60 % reduction in 
NMM II-A mRNA expression as compared to the negative control (FIGURE 4.4B; 
Scramble). Additionally, specificity was shown as indicated by no reduction in NMM II-
B mRNA expression in cells transfected with NMM II-A siRNA (FIGURE 4.5).  
Similarly, transfection with NMM II-A siRNA (100nM) showed approximately a 70% 
reduction in protein expression as measured by Western blot analysis (FIGURE 4.6).  
Similar results were obtained for genetic inhibition of NMM II-B isoform in 
primary HSC cultures. RT-PCR measurements demonstrated that mRNA expression of 
NMM II-B in HSCs transfected with siRNA specific to NMM II-B duplex #1 was down-
regulated 56% as compared to negative control and 84% as determined by quantitative 
RealTime PCR (FIGURE 4.7). Furthermore, knock-down was specific to the NMM II-B 
isoform (FIGURE 4.8), as NMM II-A mRNA expression was not inhibited by the NMM 
II-B siRNA duplex (FIGURE 4.9). Western blot analysis also confirmed protein 
expression knock-down of the NMM II-B isoform by 56% in HSCs transfected with the 
specific NMM II-B siRNA duplex. 
As previously determined (FIGUREs 3.7 and 3.9), both the mRNA and protein 
expression levels of NMM II-C were undetected in quiescent and minimal in early 
culture-activated (day 1) HSCs. RealTime PCR results demonstrated while HSC culture-
activation induced significant mRNA expression of NMM II-A and II-B, expression of 
NMM II-C was variable and not statistically significant. Protein expression of NMM II-C 
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was also minimally detected at day1 of culture activation. Therefore, it was not surprising 
that siRNA-mediated knock-down of the NMM II-C isoform in day 3 culture-activated 
HSCs was undetected (data not shown).  
 After determining the optimal siRNA duplexes and concentrations of NMM II-A 
and II-B, we were able to demonstrate the specificity of each siRNA duplex in the six 
permutations of these genes to determine if more than one gene can be down-regulated at 
the same time by RealTime PCR. As previously described, day 3 HSCs were transiently 
transfected with each siRNA alone or in combination with a second siRNA duplex. 
RealTime measurements indicate that mRNA expression down-regulation was specific in 
each instance as compared to the negative control (FIGURE 4.10). Successful knock-
down of NMM II-A and II-B with siRNA would therefore allow us to associate NMM II 
isoform expression with a particular cell function, such as contraction, migration and/or 
proliferation.  
4.2.3 Functional assays to determine NMM II isoform function 
Our lab has previously shown that the myosin II inhibitor, blebbistatin, can inhibit 
the contractile properties of HSCs. Furthermore, Melton et al. reported that blebbistatin 
directly inhibits HSC migration [45]. Myosin II molecules of higher organisms can be 
subdivided in four categories: skeletal, cardiac, smooth and nonmuscle. Since HSCs are 
nonmuscle cells, we determined the functional roles these myosin isoforms play in 
cellular contraction, migration and proliferation.  
To determine the effect of genetic inhibition of NMM II isoforms on HSC cellular 
function, we used contraction, migration and proliferation assays previously described 
(Section 2.13). For contractility assessment, HSCs were transiently transfected on day 3 
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of culture-activation, as shown previously, and allowed to recover overnight. Cells were 
subsequently treated with ET-1 for 24 hours (at this point cells were day 5 of culture-
activation). The optimal concentration of ET-1 (1nM), as previously determined 
(FIGURE 3.2), was used to induce contraction of the collagen lattices. The effects of 
genetic inhibition of NMM II isoforms was determined by the changes in gel 
circumference after 24 hours and contraction rate, as compared to negative control 
(Scramble).  The rate of contraction was measured by calculating changes in collagen 
lattice diameter at different time points (0, 0.5, 1, 1.5, 2 and 24 hours).  
The motor properties of NMM II-B indicate that it is kinetically tuned to be more 
hypercontractile than NMM II-A [14]; therefore, we concentrated our preliminary studies 
on understanding the role of NMM II-B in sustained HSC contraction. However, 
contraction assay results indicated that siRNA-mediated knock-down of NMM II-B did 
not alter basal or ET-1 induced contraction of HSCs at optimally determined siRNA 
concentration of 100nM after 24 hours (FIGURE 4.11). In an attempt to optimize 
contraction assay for knock-down experiments we altered the in vitro assay by increasing 
siRNA concentration; however, this also had no effect on HSC contraction. We therefore 
tested selected (II-A, II-B, II-C only; II-A and II-B) permutations of the NMM II 
isoforms to determine if other isoforms or a combination of isoforms would have an 
effect. Again, siRNA-mediated knock-down of selected permutations did not have an 
effect on basal or ET-1 induced HSC contraction (FIGURE 4.12). Finally, we tested the 
effect of these knock-down permutations by altering the previously determined collagen 
concentration of the assay and the cell number; however, both alterations had no effect on 
siRNA mediated knock-down of NMM II isoform HSC contraction (FIGURE 4.13 and 
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4.14). We also tested the effect of longer transient transfection incubation periods (48 and 
72 hours post-transfection), as previous studies have shown an increase in transfection 
efficiency [221]; however, these results also demonstrated no change in contraction 
(FIGURE 4.15). 
Since kinetic evidence has suggested that NMM II-A may responsible for initial 
force generation of the cell rather than sustained contractile tension, we also measured the 
rate of basal and ET-1 induced contraction (FIGURE 4.16). Again, day 3 HSCs were 
transiently transfected with siRNA permutations or scramble siRNA and allowed to 
incubate for 24 hours. The cells were treated with ET-1 and contraction rate was 
measured by calculating changes in collagen lattice diameter at six different time points. 
All siRNA permutations tested did not alter the contraction rate of HSCs as compared to 
scramble. 
 Earlier days of culture-activation (day 5) were again used for migration and 
proliferation analyses since later stages of activation (day 14) result in slower migration 
and decreased proliferation. To determine the effect of genetic inhibition on migration, 
plate-scrape model of migration was performed. Cells were cultured for three days and 
subsequently transfected with the respected siRNA. After 48 hours, a cleared zone was 
created across the plate and images were immediately captured in four locations per plate. 
Twenty-four hours later, images were taken in the same locations and assessed for the 
number of cells that migrated and distance traveled into the ‘damaged area’ (cleared 
zone). As compared to negative control (Scramble), all isoform permutations seemed to 
have impaired migratory properties (FIGURE 4.17). Significant effects were seen in both 
II-A, II-B and II-C alone and II-A/-B, and II-B/-C combinations; indicating that all three 
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isoforms are necessary for HSC migration. Additionally, these results demonstrated that 
isoform inhibition of a single gene cannot be compensated for by another isoform for 
normal HSC migration. 
For proliferation analysis, cells were treated as described for migration assays and 
direct cell counts were performed. siRNA targeted against NMM II-B in a fibroblast cell 
line impairs cytokinesis and thus cellular proliferation [221], siRNA-mediated knock-
down of all six permutations of NMM II isoforms had no effect on proliferation as 
compared to the negative control (FIGURE 4.18). 
Overall, our results indicate that primary HSC cultures can be successfully 
transfected with siRNA targeted against NMM II-A and II-B. Additionally, inhibition of 
these isoforms alone or in combination with other isoforms can affect HSC migration; 
thereby suggesting a functional role of these genes in cellular migration necessary for 
tissue repair during hepatic fibrosis.  
4.3 DISCUSSION  
Chronic liver disease is the 12th leading cause of death in the United States as it 
accounts for nearly 30,000 deaths per year (CDC, National Center for Health Statistics, 
2005). Besides removal of insult, liver transplantation remains the only effective 
treatment for end-stage liver disease; however, a huge gap remains between the number 
of people in need of a liver transplant and the number of organs available. As the disease 
progresses, complications may arise such as: jaundice, hepatic encephalopathy, and/ or 
portal hypertension. Portal hypertension is characterized by both increased portal blood 
flow and augmented intrahepatic vascular resistance. It not only perpetuates insult to the 
hepatic tissue by depleting oxygen to the cells, but also gives rise to esophageal varicies 
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and ascites.  If left untreated, variceal bleeding can lead to hemorrhage and death in a 
significant proportion of patients, as it accounts for 20-50% in-hospital mortality [28]. 
Treatment of cirrhosis generally focuses on preventing progression and complications of 
the disease to improve quality of life and prolong survival of patients awaiting 
transplantation by treating esophageal varicies and ascites. Therapeutics directed at 
restoring proper hepatic microcirculation may also provide an additive benefit. 
HSCs are the main contributors of intrahepatic resistance in the liver as evidence 
has demonstrated that the average force generated by ET-1-induced contraction of a 
single HSC is 14000 dyn/cm
2
 [15]. Endothelin-1 receptor antagonist (ERA) improves 
both collagen accumulation and portal hypertension in animal models of fibrosis. Since 
endothelin receptors are present on all smooth muscle cells, clinical studies have not 
provided statistically significant evidence to support the efficacy of ERA in the treatment 
of portal hypertension [222, 223]. Our previous findings have shown that three different 
isoforms of NMM II (II-A, II-B and II-C) are upregulated in the activated HSC, thus 
providing three potentially different targets for modulation. Understanding the functional 
roles of each NMM II isoform may be beneficial in modulating the overcompensating 
role HSCs play in liver fibrosis.  
Genetic mutations in the NMM II-A gene coincided with the autosomal dominant 
giant-platelet disorders: May Hegglin anomaly, Fechtner syndrome, Epstein Syndrome 
and Sebastian syndrome [191]. In order to more closely examine the cellular role of each 
isoform, multiple genetic studies have been employed. Using targeted gene disruption to 
knockout NMM II-B in murine embryos, Tullio et al. showed that the majority of the 
homozygous embryos died in utero and the remaining pups died within 24 hours due to 
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cardiac and brain defects [214, 224]. Furthermore, mutations in the NMM II-C gene were 
linked to hearing loss as indicated by decreased auditory brainstem responses, indicating 
that this isoform is also functionally necessary [192]. 
In an attempt to identify the cellular proteins responsible for increased 
contraction, migration and proliferation in the activated HSC, this study examined the 
effects of genetic inhibition of each NMM II isoform in vitro. Using siRNA-mediated 
knock-down our results indicated that both mRNA and protein expression of NMM II-A 
and II-B were significantly down-regulated in day 5 culture-activated HSCs. As 
previously characterized (FIGURES 3.7 and 3.9), NMM II-C expression was minimally 
detected in early days of HSC culture-activation; therefore, it was not surprising that 
siRNA-mediated knock-down of this isoform was indeterminable.  Additionally, 
inhibition of each isoform alone (II-A, II-B or II-C) or in combination with a second 
isoform (II-A/B, II-B/C or II-A/C) was specific to the targeted siRNA duplex (FIGURE 
4.10). Successful genetic inhibition of these permutations allowed us to further 
investigate the role of each isoform using contraction, migration and proliferation assays.  
As previously reported, day 5 culture-activated HSCs exhibited a basal contractile 
phenotype as measured by collagen assay. Additionally, as seen in fibrotic animal models 
and clinical studies, ET-1 further stimulates the contractile properties of activated HSCs 
[16, 17]. Therefore, we used a collagen contraction assay to determine the effects of 
genetic inhibition of NMM II isoforms on basal and ET-1 induced contraction (FIGURE 
4.11). Our results indicated that genetic inhibition of each isoform alone or in 
combination with a second isoform had no effect on basal or ET-1 induced HSC 
contraction (FIGURE 4.13). These results indicate that although HSCs are nonmuscle 
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cells, NMM II isoforms may not be the molecular motor responsible for HSC contraction. 
As an alternative hypothesis, HSCs express a large number of early and late smooth 
muscle cell markers including smooth muscle (SM) !-actin, SM22!, desmin, SM myosin 
heavy chain, h1-calponin, h-caldesmon and myocardin; therefore, the smooth muscle 
myosin II proteins could regulate HSC hypercontracion associated with portal 
hypertension [201]. 
HSC proliferation is induced by platelet-derived growth factor (PDGF), which 
activates the FAK-PI3-K-Akt signaling cascade [132]. Similarly, this signaling pathway 
is also critical for HSC migration in the activated HSC; however, it has not been 
determined if these cellular processes are independent. Generally, mitosis is rare in 
migrating cells; however, specific NMM II isoforms may coordinately regulate these 
processes in the HSC. Based on a genetic profile of the transdifferentiation process of the 
HSC (i.e. freshly isolated cells through day 10 of culture-activation), our lab has 
previously identified days 3-6 of culture-activation to be days in which the cell has a high 
probability of migrating and proliferating during the activation process in vitro as 
indicated by an increase in mRNA expression of mitotic and migratory genes (Akt, cyclin 
D1, FAK, RhoA).  Therefore, to assess the role of NMM II isoforms during migration 
and proliferation, we again used day 5 culture-activated HSCs. Although NMM II-A 
plays a role in proliferation of fibroblasts [219], our results indicated that siRNA-
mediated knock-down of all six permutations of NMM II isoforms had no effect on 
proliferation as compared to the control. More sensitive studies to measure cellular 
proliferation, such as BrdU incorporation assay, may be needed to detect changes in 
genetic inhibition related to NMM II.  
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Using a plate-scrape model of migration, our results demonstrated that genetic 
siRNA-mediated knock-down of all six permutations of NMM II isoforms had an 
inhibitory effect on migration. Approximately 25% inhibition was evident for all 
permutations indicating that all three isoforms unexpectedly play an overlapping role in 
HSC migration. Previous data demonstrating localization of NMM II-A and II-B in the 
periphery and cortex of activated HSCs indicated that this isoform may be important for 
migration and contraction, respectively (FIGURE 3.10). Significant results were obtained 
for all permutations except II-A /-C in combination indicating that these isoforms 
coordinately regulate the procession of HSCs towards a chemotactic stimulus. Although 
we report a significant effect on HSC migration, it has yet to be determined if this would 
be physiologically relevant in vivo.  
Previous data demonstrating localization of NMM II-B in the cortex of activated 
HSCs indicated that this isoform may be important for contraction; however, significant 
changes were undetected in the assays using isoform knockdown HSCs.  Therefore, it 
may be possible that the level of genetic inhibition was not sufficient to visualize 
alterations in these properties and the residual NMM II content was adequate for 
contraction to occur. Furthermore, genetic inhibition of NMM II-C expression was 
undetermined; suggesting that inhibition of this isoform may be insufficient to delineate 
cellular function. Future studies will examine alternative strategies to knock-down NMM 
II isoforms in a Cre-lox recombination system and confirm or dispute these results.  
Overall, these studies have begun to delineate the specific roles NMM II isoforms 
play in HSC contraction, migration and proliferation. These results showed that NMM II 
isoforms are functionally necessary for normal HSC migration on the specific day (day 5) 
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in which these cells are needed to contribute to the wound healing response in an injured 
liver; whereas, contraction and proliferation of HSCs may not be dependent on NMM II 
expression. While NMM II isoform inhibition may not provide an attractive therapeutic 
target for regulating portal hypertension, future studies will determine if complete 
inhibition of the NMM II isoforms or inhibition of other myosin II classes would improve 
the deleterious effects of HSC hypercontraction seen in hepatic fibrosis. 
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FIGURE 4.1: LX-2 Cells Do Not Respond to ET-1 Treatment. Day 5 culture-activated 
HSCs and increasing quantities of LX-2 cells were seeded onto collagen lattices and 
treated with ET-1 (1 nM). As compared HSC contraction, LX-2 cells did not respond to 
the vasoconstrictor, ET-1 treatment after 24 hours. 
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FIGURE 4.2: Lipofectamine Reagent Down Regulated GAPDH mRNA Expression. Day 
3 culture-activated HSCs were incubated with GAPDH or scramble siRNA (100nM) and 
increasing volumes of lipofectamine reagent (10 and 20 µl) for 48 hours. As determined 
by RT-PCR, the expression of GAPDH mRNA was inhibited by 39% in samples 
incubated with 10 µl  Lipofectamine and GAPDH siRNA as compared to scramble 
siRNA. (Top panel: representative gel; *  p<0.05) 
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FIGURE 4.3: siRNA Inhibited GAPDH mRNA Expression in HSCs. Day 3 culture-
activated HSCs were incubated with either increasing doses (50-300 nM) of  GAPDH 
siRNA or scramble siRNA and lipofectamine reagent (10 µl) for 48 hours. RT-PCR 
measurements showed the greatest inhibition with 300nM siRNA of GAPDH mRNA 
expression as compared to scramble siRNA. (Top panel: representative gel) 
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FIGURE 4.4: siRNA (#2) Successfully Down Regulated mRNA Expression of NMM II-
A. Day 3 culture-activated HSCs were incubated with either increasing doses of NMM II-
A siRNAs (#1 and #2; 50-100 nM) or scramble siRNA and lipofectamine reagent (10 ml) 
for 48 hours. As compared to the scramble siRNA, the mRNA expression of NMM II-A 
in samples incubated with 100 nM siRNA (#2) was significantly decreased 53% as 
determined by RT-PCR (A), and 60% as determined by RealTime PCR (B). (Top panel: 
representative gel; * p<0.05) 
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FIGURE 4.5: Specific Genetic Inhibition of NMM II-A. Day 3 culture-activated HSCs 
were treated with increasing doses (50-100nM) of NMM II-A siRNA or scramble siRNA 
and lipofectamine reagent (10 ml) for 48 hours. RT-PCR measurements indicated that 
NMM II-A siRNA did not inhibit NMM II-B expression as compared to the scramble. 
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FIGURE 4.6: siRNA Inhibited NMM II-A protein expression. Day 3 culture-activated 
HSCs were incubated with increasing doses (50 and 100nM) of NMM II-A siRNA or 
scrambled siRNA and lipofectamine reagent (10 µl) for 48 hours. Whole cell extracts 
were isolated and subjected to actin selection. Protein complexes were run on a SDS 8% 
polyacrylamide gel and probed with an antibody for NMM II-A (1:1000; Covance). 
Western blot analysis indicated that siRNA inhibited NMM II-A expression by 70% as 
compared to scramble. (Top panel: representative Western blot; * p<0.05) 
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FIGURE 4.7: siRNA (#1) down regulated mRNA expression of NMM II-B. Genetic 
Inhibition of NMM II-B: siRNA (#1) successfully down regulated mRNA expression. 
Day 3 culture-activated HSCs were incubated with either increasing doses of NMM II-B 
siRNAs (#1 and #2; 10-100 nM) or scramble siRNA and lipofectamine reagent (10 ml) 
for 48 hours. As compared to the scramble siRNA, the expression of NMM II-B mRNA 
in samples incubated with 100 nM NMM II-B siRNA (#1)  was significantly decreased 
58% as determined by RT-PCR (A), and 75% as determined by RealTime PCR (B). (Top 
panel: representative gel; * p<0.05) 
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FIGURE 4.8: Specific Genetic Inhibition of NMM II-B. Day 3 culture-activated HSCs 
were treated with increasing doses (10-100nM) of NMM II-B or scramble siRNA for 48 
hours. RT-PCR measurements indicated that siRNA did not inhibit NMM II-A 
expression as compared to the scramble. 
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FIGURE 4.9: siRNA Inhibited NMM II-B protein expression. Day 3 culture-activated 
HSCs were treated with increasing doses of NMM II B (10-100 nM) siRNA or scramble 
siRNA for 48 hours. Whole cell extracts were isolated and subjected to actin selection. 
Protein complexes were run on a SDS 8% polyacrylamide gel and probed with an 
antibody for NMM II-B (1:1000; Covance). Western blot analyses indicate that siRNA 
inhibits NMM II-B expression 56% as compared to scramble. (Top panel: representative 
Western blot; * p<0.05) 
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FIGURE 4.10: Specific Genetic Inhibition of NMM II Isoform Permutations. NMM II 
mRNA was inhibited and specific to targeted gene. Day 3 culture-activated HSCs were 
incubated with either permutations of siRNAs (II-A, II-B and II-C alone; II-A/-B, II-A/-C 
and II-B/-C) or scramble siRNA and lipofectamine reagent (10 ml) for 48 hours. (A) As 
compared to the scramble siRNA, the mRNA expression of NMM II-A was significantly 
decreased 55%, 40% and 44% in samples incubated with II-A alone, II-A/-B, II-A/ -C 
and II-B/C, respectively, while expression of NMM II-A remained constant in remaining 
samples. (B) Similar results were obtained for siRNA-mediated down-regulation of 
NMM II-B. Expression levels of II-B alone, II-A/-B, II-B/-C were 71%, 60% and 75% 
respectively, while expression of II-B in remaining samples were unchanged as compared 
to control. (* p<0.05) 
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FIGURE 4.11: NMM II-B siRNA Does Alter Basal or ET-1 Induced Contraction of 
HSCs. Day 3 HSCs were transiently transfected with siRNA targeted to NMM II-B 
isoform and allowed to incubate for 24 hours. The cells were trypsinized, 100K cells 
seeded onto collagen lattices and serum starved for 24 hours and subsequently treated 
with ET-1. While expression of NMM II-B was shown to be down-regulated by II-B 
siRNA (100nM), it did not decrease basal or ET-1 induced contraction after 24 hours as 
compared to samples treated with scramble siRNA. Similar results were obtained when 
siRNA concentrations were increased to 200 nM. (* p<0.05) 
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FIGURE 4.12: NMM II-A/-B/-C or II-A and -B siRNA Does Not Alter Basal or ET-1 
Induced Contraction of HSCs. Day 3 HSCs were transiently transfected with siRNA 
targeted to NMM II-A, II-B and II-C alone, II-A/-B in combination or scramble siRNA 
and allowed to incubate for 24 hours. The cells were trypsinized and 100K cells seeded 
onto collagen lattices overnight, serum starved for 24 hours and subsequently treated with 
ET-1 (1nM). All siRNA permutations tested did not decrease basal or ET-1 induced 
contraction of HSCs as compared to scramble. 
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FIGURE 4.13: siRNA Treatment Does Not Alter Basal or ET-1 Induced Contraction of 
HSCs on Less Stiff Collagen Matrix. Day 3 HSCs were transiently transfected with 
siRNA targeted to NMM II-A, II-B and II-C alone, II-A/-B, II-B/-C and II-A/-C in 
combination or scramble siRNA and allowed to incubate for 24 hours. The cells were 
trypsinized and 100K cells seeded onto collagen lattices of varying concentrations (3.25 
or 3.65 mg/ml) overnight, serum starved for 24 hours and subsequently treated with ET-
1. All siRNA permutations tested did not decrease basal or ET-1 induced contraction of 
HSCs as compared to scramble. 
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FIGURE 4.14: Decreased Cell Concentration Does Not Alter Contraction of HSCs 
Treated with siRNA. Day 3 HSCs were transiently transfected with siRNA targeted to 
NMM II-A, II-B and II-C alone, II-A/-B in combination or scramble siRNA and allowed 
to incubate for 24 hours. The cells were trypsinized, 100K cells seeded onto collagen 
lattices overnight, serum starved for 24 hours and subsequently treated with ET-1 (1nM). 
All siRNA permutations tested did not decrease basal or ET-1 induced contraction of 
HSCs. 
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FIGURE 4.15: Increased Transfection Incubation Does Not Alter Basal or ET-1 Induced 
Contraction of HSCs treated with siRNA. Day 3 HSCs were transiently transfected with 
siRNA targeted to NMM II-A, II-B and II-C alone, II-A/-B in combination or scramble 
siRNA and allowed to incubate for 48 (A) or 72 (B) hours. The cells were trypsinized, 
100K cells seeded onto collagen lattices overnight, serum starved for 24 hours and 
subsequently treated with ET-1 (1nM). All siRNA permutations tested did not decrease 
basal or ET-1 induced contraction of HSCs. 
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FIGURE 4.16: siRNA Treatment Does Not Alter Basal or ET-1 Induced HSC 
Contraction Rate. Day 3 HSCs were transiently transfected with siRNA targeted to NMM 
II-A, II-B and II-C alone, II-A/-B, II-B/-C and II-A/-C in combination or scramble 
siRNA and allowed to incubate for 24 hours. The cells were trypsinized, seeded onto 
collagen lattices overnight, serum starved for 24 hours and subsequently treated with ET-
1. All siRNA permutations tested did not alter the contraction rate of HSCs as compared 
to scramble. 
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FIGURE 4.17: NMM II Modulates HSC Migration. Day 3 HSCs were transiently 
transfected with siRNA targeted to all NMM II permutations or scramble siRNA and 
allowed to incubate for 48 hours. A 10 µl pipet tip was used to create a cleared area. 
Images were immediately taken and the cells were incubated overnight. After 24 hours, 
images were again taken to determine percentage of cells migrated into the cleared area. 
Migration was calculated as distance travelled over time. All siRNA permutations tested 
except II-A/-C combination were statistically decreased as compared to scramble. (Top 
panel: representative micrographs; * p<0.05) 
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FIGURE 4.18: siRNA Treatment Does Not Modulate HSC Proliferation. Day 3 HSCs 
were transiently transected with siRNA targeted to NMM II-A, II-B and II-C alone, II-
A/-B, II-B/-C and II-A/-C in combination or scramble siRNA and allowed to incubate for 
48 hours. Direct cell counts were taken to assess HSC proliferation. All siRNA 
permutations tested were not statistically different from the negative control (Scramble). 
 
CHAPTER 5: SUMMARY AND FUTURE DIRECTIONS 
 
 
In non-migratory quiescent hepatic stellate cells (HSCs), cellular processes wrap 
around hepatic sinusoids to regulate blood flow by contracting and dilating in response to 
local vasoactive modulators [2, 39]. Upon a fibrogenic stimulus, HSCs activate becoming 
highly proliferative, hypercontractile, myofibroblast-like cells [11, 42, 43].  This 
transdifferentiation process facilitates wound healing, and chemotactic stimulation 
promotes a reorganization of cellular polarity resulting in HSC migration [70]. In order to 
repair the damaged area, activated HSCs increase production of fibrillar collagens 
replacing the low-density basement membrane with fibrous scar matrix [48]. In addition 
to changes in matrix stiffness, increased production of vasoconstrictors by neighboring 
cells induces hypercontraction of HSC protrusions decreasing toxic blood flow to the area 
of injury [14, 46]. Chronic injury and unresolved fibrosis perpetuates HSC activation and 
ultimately leads to cirrhosis and the clinical manifestation of portal hypertension [6].  
Portal hypertension remains the main cause of morbidity and mortality in patients 
with cirrhosis. The onset of portal hypertension may be accompanied by gastrointestinal 
bleeding, ascites or encephalopathy [225]. Hepatic encephalopathy results from 
decreased liver function, which is associated with memory loss, seizures and/ or coma. 
Ascites is an accumulation of fluid in the peritoneal cavity, which results from an 
imbalance of pressure in the circulation. If a large amount of fluid accumulates, then the 
patient’s abdomen becomes enlarged and taut. Portal hypertension is alleviated by 
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diverting blood flow through the systemic system, which results in varicies of the 
gastroesophageal blood vessels [225]. Variceal hemorrhaging occurs when sustained 
portal hypertension causes rupturing of these vessels. It is evident that a decrease in 
portal pressure is not only protective against the risks of variceal bleeding but is also 
associated with a lower long-term risk of gastro-esophageal varices. However, in 
practice, less than half the patients are protected under the current therapies [225]. 
Intrahepatic vasorelaxing may provide an additive benefit in patients suffering with 
unresolved fibrosis and cirrhosis, thus targeting all complications associated with portal 
hypertension. 
Besides removal of insult, liver transplantation remains the only effective 
treatment for end-stage liver disease; however, a huge gap remains between the number 
of people who need a liver transplant and the number of organs available. According to 
the 2008 U.S. Organ Procurement and Transplantation Network and the Scientific 
Registry of Transplant Recipients Annual Report, the number of patients awaiting a liver 
transplant at year-end in 2001 was 7,084; however, over 10,000 patients were on the 
waiting list for a donor organ. In addition, not all patients with end-stage liver disease are 
suitable candidates for liver transplantation. Generally, organs are transplanted to patients 
with the highest degree of survival. Patients positive for AIDS or HIV, with irreversible 
brain damage, multi-system organ failure that are not correctable by liver transplantation, 
malignancy outside the liver, infections outside the hepatobiliary system, active alcohol 
or substance abuse are not eligible. Therefore, treatment generally focuses on preventing 
progression and complications of the disease. Targeting portal hypertension may improve 
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quality of life and prolong survival of patients awaiting transplantation by treating 
esophageal varicies, ascites and restoring proper hepatic microcirculation. 
 Modulating collagen production in the HSC is an obvious remedy to ameliorate 
liver fibrosis; however, targeting proliferation, migration and contraction may prove to be 
more beneficial in treating portal hypertension.  These cellular functions are regulated by 
the actomyosin complex [59-61, 64].  Myosin II plays numerous roles in cellular 
processes such as actin-based motility, vesicle transport, endocytosis, phagocytosis, 
sterocilia formation, cytokinesis and contraction [149]. This molecular motor can be 
further subdivided into distinct classes based on motor domain amino acid sequences: the 
sarcomeric myosins characteristic of skeletal, cardiac and smooth muscle cells, 
nonmuscle myosins and myosin II from lower eukaryotic species and fungi [149]. Since 
the HSC is a nonmuscle cell, we focused our studies on understanding the role of three 
nonmuscle myosin II (NMM II) isoforms, II-A, II-B and II-C, in HSC activation. Cellular 
contraction, migration and proliferation are primarily regulated by dynamic remodeling 
of the cytoskeleton leading to changes in cellular morphology; therefore, isoform 
selection may serve as a plausible means to regulate these processes.  
 An imbalance in vasoactive modulators contributes to HSC hypercontractility in 
the injured liver [12, 13, 128, 226]. In addition, upregulation of the Rho signaling 
pathway in the activated HSC confers an increase in contractile potential; however, these 
findings do not distinguish between increased contraction due to myosin II inhibition or 
actin destabilization [132-134]. Blebbistatin is a myosin II inhibitor previously shown to 
block protrusion-mediated lamella formation and chemotactic migration of HSCs [45]. 
By using this selective inhibitor, we demonstrated that myosin II is the primary molecular 
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motor responsible for HSC contraction. Since myosin II controls both HSC migration and 
contraction, we expanded upon these studies to determine a function for each myosin II 
isoform. Our results indicated that the three isoforms, NMM II-A, II-B and II-C, were 
upregulated in culture-activated HSCs; however, only NMM II-A and II-B were 
significantly upregulated in activated HSCs of the injured liver. This inconsistency may 
be explained in part by the minimal levels of NMM II-C present in the in vitro cultures. 
An alternative justification may be attributed to the differences between in vitro and in 
vivo models. Expression of cellular proteins, including both myosin and actin, differed 
more than three-fold between in vitro cultures and fibrotic animal models [227]. 
Additionally, in vitro activation of a HSC monolayer on plastic tissue culture dishes does 
factor in the heterogeneous environment of the fibrotic liver. Multiple cell types produce 
cytokines and growth factors that affect chemotactic signaling of HSCs. Repeating these 
experiments in a co-culture system with other hepatic cell types may be beneficial to 
understanding the mechanisms regulating NMM II expression in the HSC.  
In addition, mechanical rigidity has recently emerged as an important determinate 
of cellular phenotype. Culturing HSCs on plastic is a widely accepted model to mimic the 
fibrotic environment; however, the stiffness of the culture dish may not accurately reflect 
the stiffness of the fibrotic matrix. Therefore, matrix stiffness assays were employed to 
alter in vitro conditions to more accurately reflect the in vivo environment. In the current 
study we demonstrated that NMM II expression is matrix-stiffness dependent, further 
validating a role for NMM II in fibrosis. Since the fibrotic liver is a heterogeneous 
substrate, future studies may be employed to confirm these results by gradually varying 
the matrix stiffness.  
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 By characterizing the expression profile of the specific isoforms NMM II-A, II-B 
and II-C, we were able to identify isoforms that may be responsible for the fibrogenic 
response of activated HSC contraction, migration and proliferation. As previously 
verified, myosin II is the molecular motor responsible for HSC contraction and migration. 
Typically, contraction, migration and proliferation contribute to wound repair but appear 
to be controlled by independent mechanisms that are mutually exclusive. Endothelin-1 is 
the primary vasoconstrictor responsible for HSC contraction, which is modulated by the 
upstream Rho signaling pathway [132-134]. HSC proliferation is induced by platelet-
derived growth factor (PDGF) subsequently activating the FAK-PI3k -Akt signaling 
cascade [70]. This signaling pathway is also critical for HSC migration in the activated 
HSC; however, it has not been determined which myosin II classes regulate these cellular 
processes. Generally, mitosis rarely occurs in migrating cells [228, 229]; however, 
specific NMM II isoforms may coordinately regulate these processes in the HSC. siRNA-
mediated knock-downs of each isoform alone or in combination demonstrated that HSC 
migration was inhibited by approximately 25% as compared to cells treated with 
scramble siRNA indicating a functional role of these isoforms. Future studies will be 
needed to validate these results as the experimental method employed does not account 
for the proliferating compartment of the assay. To assess three-dimensional constraints on 
cellular behavior, the Boyden chamber model and suspension gels of varying matrix 
compositions and rigidity would be beneficial.  
HSC contraction and proliferation were not statistically altered by the genetic 
inhibition, further suggesting certain functions for each isoform during different cellular 
activities. Although siRNA-mediated knockdown did not significantly alter contraction 
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and proliferation; the expression levels may be sufficient to support these cellular 
processes and future studies should be carried out to completely obliterate these isoforms 
using a Cre-lox recombination system to confirm these preliminary results.  
Although HSCs are nonmuscle cells, they express a large number of early and late 
smooth muscle cell markers including smooth muscle (SM) !-actin, SM22!, desmin, SM 
myosin heavy chain, h1-calponin, h-caldesmon and myocardin; therefore, future studies 
will examine the role smooth muscle myosin II isoforms play in HSC contraction and 
proliferation. To confirm that in vitro results correlate with in vivo models, adenoviral 
constructs expressing siRNA under promoter specific regulation will need to be 
generated to confirm if down-regulation of specific myosin II classes in activated HSCs 
contribute to changes in HSC contraction, migration and proliferation. 
 Future biophysical studies should also examine the contractile, migratory and 
proliferative properties of HSCs in more detail. Specifically, using genetic inhibition of 
specific isoforms, a force transducer could be used to examine the rate of force 
development, maximum force, and contractile velocity of each isoform in the HSCs. 
Additionally, a novel live cell imaging method is being developed in which fluorescence 
resonance energy transfer (FRET) could be changed between a fluorescent probe on 
myosin II and a probe on actin to estimate the number of myosin heads interacting with 
actin during HSC contraction. These measurements would allow us to estimate the force 
per cross-bridge and begin to extract force-velocity and work velocity curves of HSC 
contraction. Biophysical measurements would facilitate understanding the role of myosin 
II isoforms in the progression of hepatic fibrosis and portal hypertension. Complete 
eradication of HSCs would be detrimental to normal liver function and ultimately fibrotic 
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resolution; therefore, it is imperative to develop treatment regimes that target specific 
myosin II isoforms. 
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